<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-id journal-id-type="hwp">ahaoa</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27091182</article-id><article-id pub-id-type="pmc">4843533</article-id><article-id pub-id-type="doi">10.1161/JAHA.115.002288</article-id><article-id pub-id-type="publisher-id">JAH31429</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Heart Failure</subject></subj-group></subj-group></article-categories><title-group><article-title>Neovascularization Potential of Blood Outgrowth Endothelial Cells From Patients With Stable Ischemic Heart Failure Is Preserved</article-title><alt-title alt-title-type="left-running-head">Dauwe et&#x000a0;al</alt-title></title-group><contrib-group><contrib id="jah31429-cr-0001" contrib-type="author" corresp="yes"><name><surname>Dauwe</surname><given-names>Dieter</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah31429-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah31429-cr-0002" contrib-type="author"><name><surname>Pelacho</surname><given-names>Beatriz</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah31429-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="jah31429-cr-0003" contrib-type="author"><name><surname>Wibowo</surname><given-names>Arief</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31429-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah31429-cr-0004" contrib-type="author"><name><surname>Walravens</surname><given-names>Ann&#x02010;Sophie</given-names></name><xref ref-type="aff" rid="jah31429-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah31429-cr-0005" contrib-type="author"><name><surname>Verdonck</surname><given-names>Kristoff</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31429-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah31429-cr-0006" contrib-type="author"><name><surname>Gillijns</surname><given-names>Hilde</given-names></name><xref ref-type="aff" rid="jah31429-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah31429-cr-0007" contrib-type="author"><name><surname>Caluwe</surname><given-names>Ellen</given-names></name><xref ref-type="aff" rid="jah31429-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah31429-cr-0008" contrib-type="author"><name><surname>Pokreisz</surname><given-names>Peter</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah31429-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah31429-cr-0009" contrib-type="author"><name><surname>van Gastel</surname><given-names>Nick</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah31429-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah31429-cr-0010" contrib-type="author"><name><surname>Carmeliet</surname><given-names>Geert</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah31429-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah31429-cr-0011" contrib-type="author"><name><surname>Depypere</surname><given-names>Maarten</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah31429-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jah31429-cr-0012" contrib-type="author"><name><surname>Maes</surname><given-names>Frederik</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah31429-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jah31429-cr-0013" contrib-type="author"><name><surname>Vanden Driessche</surname><given-names>Nina</given-names></name><xref ref-type="aff" rid="jah31429-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah31429-cr-0014" contrib-type="author"><name><surname>Droogne</surname><given-names>Walter</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31429-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah31429-cr-0015" contrib-type="author"><name><surname>Van Cleemput</surname><given-names>Johan</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah31429-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah31429-cr-0016" contrib-type="author"><name><surname>Vanhaecke</surname><given-names>Johan</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah31429-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jah31429-cr-0017" contrib-type="author"><name><surname>Prosper</surname><given-names>Felipe</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah31429-aff-0006">
<sup>6</sup>
</xref><xref ref-type="aff" rid="jah31429-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="jah31429-cr-0018" contrib-type="author"><name><surname>Verfaillie</surname><given-names>Catherine</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah31429-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jah31429-cr-0019" contrib-type="author"><name><surname>Luttun</surname><given-names>Aernout</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah31429-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah31429-cr-0020" contrib-type="author" corresp="yes"><name><surname>Janssens</surname><given-names>Stefan</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah31429-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="jah31429-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Cardiovascular Sciences, Clinical Cardiology</named-content><institution>KU Leuven</institution><named-content content-type="city">Leuven</named-content><country country="BE">Belgium</country></aff><aff id="jah31429-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Center for Molecular and Vascular Biology</named-content><institution>KU Leuven</institution><named-content content-type="city">Leuven</named-content><country country="BE">Belgium</country></aff><aff id="jah31429-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Department of Clinical and Experimental Endocrinology</named-content><institution>KU Leuven</institution><named-content content-type="city">Leuven</named-content><country country="BE">Belgium</country></aff><aff id="jah31429-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Department of Electrical Engineering</named-content><named-content content-type="organisation-division">Center for the Processing of Speech and Images</named-content><institution>KU Leuven</institution><named-content content-type="city">Leuven</named-content><country country="BE">Belgium</country></aff><aff id="jah31429-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Department of Development and Regeneration</named-content><named-content content-type="organisation-division">Stem Cell Biology and Embryology</named-content><institution>KU Leuven</institution><named-content content-type="city">Leuven</named-content><country country="BE">Belgium</country></aff><aff id="jah31429-aff-0006"><label><sup>6</sup></label><named-content content-type="organisation-division">Cell Therapy Department</named-content><named-content content-type="organisation-division">Center for Applied Medicine Research</named-content><named-content content-type="organisation-division">Clinica Universidad de Navarra</named-content><institution>University of Navarra</institution><named-content content-type="city">Pamplona</named-content><country country="ES">Spain</country></aff><aff id="jah31429-aff-0007"><label><sup>7</sup></label><named-content content-type="organisation-division">Hematology Department</named-content><named-content content-type="organisation-division">Clinica Universidad de Navarra</named-content><institution>University of Navarra</institution><named-content content-type="city">Pamplona</named-content><country country="ES">Spain</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Dieter Dauwe, MD, PhD, or Stefan Janssens, MD, PhD, Department of Cardiovascular Diseases, University Hospitals Leuven, KU Leuven, Herestraat 49, 3000 Leuven, Belgium. E&#x02010;mails: <email>dieter.dauwe@med.kuleuven.be</email>; <email>stefan.janssens@med.kuleuven.be</email></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2016</year></pub-date><volume>5</volume><issue>4</issue><issue-id pub-id-type="doi">10.1002/jah3.2016.5.issue-4</issue-id><elocation-id>e002288</elocation-id><history><date date-type="received"><day>05</day><month>7</month><year>2015</year></date><date date-type="accepted"><day>11</day><month>2</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-5-e002288.pdf"/><abstract id="jah31429-abs-0001"><sec id="jah31429-sec-0001"><title>Background</title><p>Blood outgrowth endothelial cells (<styled-content style="fixed-case">BOEC</styled-content>s) mediate therapeutic neovascularization in experimental models, but outgrowth characteristics and functionality of <styled-content style="fixed-case">BOEC</styled-content>s from patients with ischemic cardiomyopathy (<styled-content style="fixed-case">ICMP</styled-content>) are unknown. We compared outgrowth efficiency and in&#x000a0;vitro and in&#x000a0;vivo functionality of <styled-content style="fixed-case">BOEC</styled-content>s derived from <styled-content style="fixed-case">ICMP</styled-content> with <styled-content style="fixed-case">BOEC</styled-content>s from age&#x02010;matched (<styled-content style="fixed-case">ACON</styled-content>) and healthy young (<styled-content style="fixed-case">CON</styled-content>) controls.</p></sec><sec id="jah31429-sec-0002"><title>Methods and Results</title><p>We isolated 3.6&#x000b1;0.6 <styled-content style="fixed-case">BOEC</styled-content> colonies/100&#x000d7;10<sup>6</sup> mononuclear cells (<styled-content style="fixed-case">MNC</styled-content>s) from 60&#x02010;mL blood samples of <styled-content style="fixed-case">ICMP</styled-content> patients (n=45; age: 66&#x000b1;1&#x000a0;years; <styled-content style="fixed-case">LVEF</styled-content>: 31&#x000b1;2%) versus 3.5&#x000b1;0.9&#x000a0;colonies/100&#x000d7;10<sup>6</sup>
<styled-content style="fixed-case">MNC</styled-content>s in <styled-content style="fixed-case">ACON</styled-content> (n=32; age: 60&#x000b1;1&#x000a0;years) and 2.6&#x000b1;0.4&#x000a0;colonies/100&#x000d7;10<sup>6</sup>
<styled-content style="fixed-case">MNC</styled-content>s in <styled-content style="fixed-case">CON</styled-content> (n=55; age: 34&#x000b1;1&#x000a0;years), <italic>P</italic>=0.29. Endothelial lineage (<styled-content style="fixed-case">VEGFR</styled-content>2<sup>+</sup>/<styled-content style="fixed-case">CD</styled-content>31<sup>+</sup>/<styled-content style="fixed-case">CD</styled-content>146<sup>+</sup>) and progenitor (<styled-content style="fixed-case">CD</styled-content>34<sup>+</sup>/<styled-content style="fixed-case">CD</styled-content>133<sup>&#x02212;</sup>) marker expression was comparable in <styled-content style="fixed-case">ICMP</styled-content> and <styled-content style="fixed-case">CON</styled-content>. Growth kinetics were similar between groups (<italic>P</italic>=0.38) and not affected by left ventricular systolic dysfunction, maladaptive remodeling, or presence of cardiovascular risk factors in <styled-content style="fixed-case">ICMP</styled-content> patients. In vitro neovascularization potential, assessed by network remodeling on Matrigel and three&#x02010;dimensional spheroid sprouting, did not differ in <styled-content style="fixed-case">ICMP</styled-content> from (A)<styled-content style="fixed-case">CON</styled-content>. Secretome analysis showed a marked proangiogenic profile, with highest release of angiopoietin&#x02010;2 (1.4&#x000b1;0.3&#x000d7;10<sup>5</sup>&#x000a0;pg/10<sup>6</sup>
<styled-content style="fixed-case">ICMP</styled-content>&#x02010;<styled-content style="fixed-case">BOEC</styled-content>s) and placental growth factor (5.8&#x000b1;1.5&#x000d7;10<sup>3</sup>&#x000a0;pg/10<sup>6</sup>
<styled-content style="fixed-case">ICMP BOEC</styled-content>s), independent of age or ischemic disease. Senescence&#x02010;associated &#x003b2;&#x02010;galactosidase staining showed comparable senescence in <styled-content style="fixed-case">BOEC</styled-content>s from <styled-content style="fixed-case">ICMP</styled-content> (5.8&#x000b1;2.1%; n=17), <styled-content style="fixed-case">ACON</styled-content> (3.9&#x000b1;1.1%; n=7), and <styled-content style="fixed-case">CON</styled-content> (9.0&#x000b1;2.8%; n=13), <italic>P</italic>=0.19. High&#x02010;resolution microcomputed tomography analysis in the ischemic hindlimb of nude mice confirmed increased arteriogenesis in the thigh region after intramuscular injections of <styled-content style="fixed-case">BOEC</styled-content>s from <styled-content style="fixed-case">ICMP</styled-content> (<italic>P</italic>=0.025; n=8) and <styled-content style="fixed-case">CON</styled-content> (<italic>P</italic>=0.048; n=5) over vehicle control (n=8), both to a similar extent (<italic>P=</italic>0.831).</p></sec><sec id="jah31429-sec-0003"><title>Conclusions</title><p>
<styled-content style="fixed-case">BOEC</styled-content>s can be successfully culture&#x02010;expanded from patients with <styled-content style="fixed-case">ICMP</styled-content>. In contrast to impaired functionality of <styled-content style="fixed-case">ICMP</styled-content>&#x02010;derived bone marrow <styled-content style="fixed-case">MNC</styled-content>s, <styled-content style="fixed-case">BOEC</styled-content>s retain a robust proangiogenic profile, both in&#x000a0;vitro and in&#x000a0;vivo, with therapeutic potential for targeting ischemic disease.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah31429-kwd-0001">arteriogenesis</kwd><kwd id="jah31429-kwd-0002">blood outgrowth endothelial cells</kwd><kwd id="jah31429-kwd-0003">cell transplantation</kwd><kwd id="jah31429-kwd-0004">ischemic heart disease</kwd><kwd id="jah31429-kwd-0005">therapeutic neovascularization</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Chronic Ischemic Heart Disease</kwd><kwd>Heart Failure</kwd><kwd>Cell Therapy</kwd><kwd>Vascular Biology</kwd><kwd>Cell Biology/Structural Biology</kwd></kwd-group><funding-group><award-group><funding-source>Research Foundation Flanders</funding-source></award-group></funding-group><funding-group><award-group><funding-source>KULeuven</funding-source><award-id>PF\10\014</award-id></award-group></funding-group><funding-group><award-group><funding-source>ISCIII</funding-source><award-id>PI13/02144</award-id><award-id>CP09/00333</award-id></award-group></funding-group><funding-group><award-group><funding-source>BOF&#x02010;KU Leuven</funding-source><award-id>3M120209</award-id></award-group></funding-group><funding-group><award-group><funding-source>Interuniversity Attraction Poles</funding-source><award-id>IUAP/P7/07</award-id></award-group></funding-group><counts><page-count count="15"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jah31429</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.8.9 mode:remove_FC converted:04.05.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jah31429-cit-1001">(<source>J Am Heart Assoc</source>. <year>2016</year>;<volume>5</volume>:e002288 doi: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.115.002288">10.1161/JAHA.115.002288</ext-link>)</mixed-citation>
</p></notes></front><body><sec id="jah31429-sec-0004"><title>Introduction</title><p>Blood outgrowth endothelial cells (BOECs) represent an easy accessible, culture&#x02010;expandable cell source with endothelial lineage specification. BOECs belong to the family of endothelial progenitor cells (EPCs), which harbors a heterogeneous selection of different cell types, participating in and modulating neovascularization. Distinct EPC subtypes are defined using different culture techniques and/or combinations of cell surface markers.<xref rid="jah31429-bib-0001" ref-type="ref">1</xref>, <xref rid="jah31429-bib-0002" ref-type="ref">2</xref>, <xref rid="jah31429-bib-0003" ref-type="ref">3</xref> BOECs, also referred to as circulating endothelial colony&#x02010;forming cells (ECFCs) or late outgrowth EPCs, are the only cell type featuring the characteristics of a &#x0201c;true&#x0201d; EPC, given that these cells are self&#x02010;renewing, clonogenic, and able to form capillary&#x02010;like structures and integrate into functional blood vessels in&#x000a0;vitro and in&#x000a0;vivo, respectively.<xref rid="jah31429-bib-0004" ref-type="ref">4</xref>
</p><p>Refractory angina is an increasingly prevalent clinical syndrome with an estimated incidence between 5% and 10% of patients undergoing cardiac catheterization.<xref rid="jah31429-bib-0005" ref-type="ref">5</xref> In patients with ischemic heart disease, refractory to optimal medical treatment and percutaneous or surgical revascularization, progenitor cell transfer may constitute a promising biological alternative (&#x0201c;biological bypass&#x0201d;).<xref rid="jah31429-bib-0006" ref-type="ref">6</xref> Autologous BOECs are able to induce neovascularization not only by incorporation into functional vessels, but also through paracrine modulation.<xref rid="jah31429-bib-0007" ref-type="ref">7</xref>, <xref rid="jah31429-bib-0008" ref-type="ref">8</xref>
</p><p>One of the major concerns when envisioning autologous (progenitor/stem) cell therapy in cardiovascular medicine, is the presumed dysfunctional progenitor cell phenotype in older and diseased patients burdened with risk factors, as evidenced for early outgrowth EPCs of monocytic origin (also known as circulating angiogenic cells),<xref rid="jah31429-bib-0009" ref-type="ref">9</xref>, <xref rid="jah31429-bib-0010" ref-type="ref">10</xref>, <xref rid="jah31429-bib-0011" ref-type="ref">11</xref>, <xref rid="jah31429-bib-0012" ref-type="ref">12</xref> CD133<sup>+</sup>/VEGFR2+ circulating EPCs,<xref rid="jah31429-bib-0010" ref-type="ref">10</xref>, <xref rid="jah31429-bib-0013" ref-type="ref">13</xref> colony&#x02010;forming&#x02010;unit EPCs (CFU&#x02010;Hill),<xref rid="jah31429-bib-0013" ref-type="ref">13</xref>, <xref rid="jah31429-bib-0014" ref-type="ref">14</xref> bone&#x02010;marrow&#x02013;derived mononuclear cells (MNCs)<xref rid="jah31429-bib-0015" ref-type="ref">15</xref> and hematopoietic stem cells.<xref rid="jah31429-bib-0011" ref-type="ref">11</xref>
</p><p>Because no data are currently available on BOEC outgrowth and functionality in patients with the greatest unmet clinical need, we compared outgrowth efficiency and in&#x000a0;vitro and in&#x000a0;vivo functional characteristics of BOECs from patients with severe, but stable, ischemic cardiomyopathy (ICMP) and BOECs from both healthy age&#x02010;matched (ACON) and young (CON) control subjects.</p></sec><sec id="jah31429-sec-0005"><title>Methods</title><sec id="jah31429-sec-0006"><title>Study Design</title><p>BOECs were isolated from peripheral blood of patients with stable ischemic cardiomyopathy (left ventricular ejection fraction [LVEF] &#x02264;45%; 18&#x02013;80&#x000a0;years) (ICMP: n=45; Table&#x000a0;<xref rid="jah31429-tbl-0001" ref-type="table-wrap">1</xref>) in follow&#x02010;up at the outpatient heart failure clinic of the Department of Cardiovascular Diseases at University Hospitals (Leuven, Belgium). The study protocol was approved by the Medical Ethics Committee (S51940), and informed consent was obtained from all patients. The control group consisted of healthy individuals (18&#x02013;80&#x000a0;years; Table&#x000a0;<xref rid="jah31429-tbl-0001" ref-type="table-wrap">1</xref>) with no evidence/history of coronary artery disease, divided in an age&#x02010;matched (ACON: n=32) and young (CON: n=55) control populations.</p><table-wrap id="jah31429-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Clinical Characteristics of Study Subjects</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">ICMP (n=45)</th><th align="left" valign="top" rowspan="1" colspan="1">CON (n=55)</th><th align="left" valign="top" rowspan="1" colspan="1">ACON (n=32)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, y</td><td align="left" rowspan="1" colspan="1">66&#x000b1;1</td><td align="left" rowspan="1" colspan="1">34&#x000b1;1</td><td align="left" rowspan="1" colspan="1">60&#x000b1;1</td></tr><tr><td align="left" rowspan="1" colspan="1">M/F (%)</td><td align="left" rowspan="1" colspan="1">91/9</td><td align="left" rowspan="1" colspan="1">59/41</td><td align="left" rowspan="1" colspan="1">25/75</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEF (%)</td><td align="left" rowspan="1" colspan="1">31&#x000b1;2</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEDD, mm</td><td align="left" rowspan="1" colspan="1">56&#x000b1;1</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiovascular risk factors</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ND</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1">29/45</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">7/32</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes</td><td align="left" rowspan="1" colspan="1">17/45</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0/32</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hyperlipidemia</td><td align="left" rowspan="1" colspan="1">38/45</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">7/32</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Obesity</td><td align="left" rowspan="1" colspan="1">14/45</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6/32</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Smoking</td><td align="left" rowspan="1" colspan="1">38/45</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10/32</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Familial cardiovascular risk</td><td align="left" rowspan="1" colspan="1">23/45</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">Extent of coronary artery disease</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">One&#x02010;vessel disease</td><td align="left" rowspan="1" colspan="1">8/45</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Two&#x02010;vessel disease</td><td align="left" rowspan="1" colspan="1">12/45</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Three&#x02010;vessel disease</td><td align="left" rowspan="1" colspan="1">25/45</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Medical treatment</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0/55</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aspirin</td><td align="left" rowspan="1" colspan="1">26/45</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0/32</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Thienopyridin</td><td align="left" rowspan="1" colspan="1">11/45</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0/32</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Statin</td><td align="left" rowspan="1" colspan="1">42/45</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2/32</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Beta&#x02010;blocker</td><td align="left" rowspan="1" colspan="1">42/45</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0/32</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ACE inhibitor/ARB</td><td align="left" rowspan="1" colspan="1">38/45</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1/32</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Spironolactone</td><td align="left" rowspan="1" colspan="1">23/45</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0/32</td></tr><tr><td align="left" rowspan="1" colspan="1">Device treatment</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0/55</td><td align="left" rowspan="1" colspan="1">0/32</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">CRT&#x02010;P</td><td align="left" rowspan="1" colspan="1">3/45</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">CRT&#x02010;D</td><td align="left" rowspan="1" colspan="1">8/45</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ICD</td><td align="left" rowspan="1" colspan="1">7/45</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="jah31429-note-0001"><p>Blood outgrowth endothelial cell (BOEC) isolations were performed in 45 patients with ischemic cardiomyopathy (ICMP), 55 young healthy controls (CON), and 32 age&#x02010;matched controls (ACON). Left ventricular ejection fraction (LVEF) and left ventricular end&#x02010;diastolic diameter (LVEDD) were measured by transthoracic echocardiography. ACE inhibitor indicates angiotensin&#x02010;converting enzyme inhibitor; ARB, angiotensin receptor blocker; CRT&#x02010;D, cardiac resynchronization therapy incorporating an implantable cardioverter defibrillator; CRT&#x02010;P, cardiac resynchronization therapy without implantable cardioverter defibrillator; ICD, implantable cardioverter defibrillator; NA, not applicable; ND, not determined.</p></fn></table-wrap-foot></table-wrap></sec><sec id="jah31429-sec-0007"><title>BOEC Isolation and Expansion</title><p>BOECs were isolated and expanded as previously described, with minor modifications.<xref rid="jah31429-bib-0004" ref-type="ref">4</xref>, <xref rid="jah31429-bib-0008" ref-type="ref">8</xref> In short, the mononuclear fraction from 40&#x02010; to 60&#x02010;mL venous blood samples was isolated using Ficoll Paque Plus (GE Healthcare, Little Chalfont, UK) density centrifugation. Cells were resuspended in EBM<sub>2</sub> supplemented with a bullet kit (Lonza, Basel, Switzerland), excluding the provided gentamicin and amfotericin singlequots. In addition, the medium was supplemented with an extra 13% of FBS, MEM&#x02010;NEAA (Gibco, Grand Island, NY), 1% penicillin/streptomycin (Gibco), and 1:550 &#x003b2;&#x02010;Mercaptoethanol (Gibco). Cells were cultured on collagen type I precoated dishes (Cellcoat; Greiner Bio&#x02010;One GmbH, Kremsm&#x000fc;nster, Austria) in a 21% O<sub>2</sub>, 5% CO<sub>2</sub> incubator. Individual BOEC colonies were picked at days 21 to 28 and pooled for further polyclonal expansion up to passage 7 or growth arrest. Phenotyping and functional evaluation was performed at passage 3 to 5 (Figure&#x000a0;<xref rid="jah31429-fig-0001" ref-type="fig">1</xref>). Mycoplasma contamination was excluded, using the MycoAlert Mycoplasma detection kit (Lonza), following the manufacturer's instructions.</p><fig fig-type="Figure" xml:lang="en" id="jah31429-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>BOEC isolation and expansion process. Mononuclear cells (MNCs) were isolated from a single 40&#x02010; to 60&#x02010;mL venous blood sample by Ficoll density centrifugation. MNCs were seeded on collagen type I precoated dishes and cultured in a 21% O<sub>2</sub>, 5% CO<sub>2</sub> incubator using EBM<sub>2</sub> medium. Medium was changed daily during the first week and every other day after. BOEC colonies started to appear at days 10 to 16 (scale bar, 200&#x000a0;&#x003bc;m). Individual BOEC colonies were picked at days 21 to 28, pooled, and culture expanded up to passage 7 or growth arrest. Phenotypic analysis was performed between passages 3 and 5. BOEC indicates blood outgrowth endothelial cell; CFU, colony&#x02010;forming units.</p></caption><graphic id="nlm-graphic-1" xlink:href="JAH3-5-e002288-g001"/></fig></sec><sec id="jah31429-sec-0008"><title>Confirmation Endothelial Phenotype</title><p>Cells were stained with <italic>Ulex europeus</italic> agglutinin (UEA)&#x02010;lectin (Sigma&#x02010;Aldrich). Dil&#x02010;AcLDL uptake (Invitrogen, Carlsbad, CA) and cell surface markers were quantified using flow cytometry (BD FACS Canto II; BD Biosciences, San Jose, CA). CD309 (vascular endothelial growth factor receptor 2; VEGFR&#x02010;2), CD146 (melanoma cell adhesion molecule), and CD31 (platelet endothelial cell adhesion molecule 1) were selected as endothelial markers, CD34 and CD133 as progenitor markers, and CD45 as a panleukocyte exclusion marker. Antibodies and isotype controls were from Miltenyi Biotec (Cambridge, MA). Gene expression was studied using real&#x02010;time quantitative PCR (RT&#x02010;qPCR; StepOnePlus; Applied Biosystems, Foster City, CA) and TaqMan Gene Expression Assays (Life Technologies, Carlsbad, CA), focusing on angiogenic growth factors and endothelial markers (Table&#x000a0;<xref rid="jah31429-tbl-0002" ref-type="table-wrap">2</xref>, top). Results are expressed as a 2<sup>&#x02212;&#x00394;CT</sup>&#x02010;value, relative to HPRT as the housekeeping gene. In addition, the angiogenic secretome was studied in 24&#x02010;hour conditioned medium (EBM<sub>2</sub>/2%FBS) by ELISA (PLGF, angiopoietin&#x02010;2 [ANG&#x02010;2], fibroblast growth factor [FGF] 2, platelet&#x02010;derived growth factor&#x02010;BB [PDGF&#x02010;BB], VEGF<sub>165</sub>, insulin&#x02010;like growth factor 1 [IGF&#x02010;1], and HGF, hepatocyte growth factor [HGF]; Quantikine; all from R&#x00026;D Systems, Minneapolis, MN; Table&#x000a0;<xref rid="jah31429-tbl-0002" ref-type="table-wrap">2</xref>, bottom).</p><table-wrap id="jah31429-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Transcriptional Analysis and Secretome of BOECs</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">RT&#x02010;qPCR (2<sup>&#x02212;&#x00394;CT</sup> vs HPRT)</th><th align="left" valign="top" rowspan="1" colspan="1">ICMP (n=15)</th><th align="left" valign="top" rowspan="1" colspan="1">CON (n=9)</th><th align="left" valign="top" rowspan="1" colspan="1">ACON (n=10)</th><th align="left" valign="top" rowspan="1" colspan="1">1&#x02010;Way ANOVA</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Endothelial markers</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">vWF</td><td align="left" rowspan="1" colspan="1">7.120&#x000b1;2.620</td><td align="left" rowspan="1" colspan="1">7.330&#x000b1;4.370</td><td align="left" rowspan="1" colspan="1">3.390&#x000b1;0.655</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>=0.69</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">NOS&#x02010;3</td><td align="left" rowspan="1" colspan="1">0.101&#x000b1;0.029</td><td align="left" rowspan="1" colspan="1">0.072&#x000b1;0.044</td><td align="left" rowspan="1" colspan="1">0.184&#x000b1;0.045</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>=0.05</td></tr><tr><td align="left" colspan="5" rowspan="1">Angiogenic/arteriogenic growth factors</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">PLGF</td><td align="left" rowspan="1" colspan="1">1.010&#x000b1;0.319</td><td align="left" rowspan="1" colspan="1">0.639&#x000b1;0.230</td><td align="left" rowspan="1" colspan="1">0.755&#x000b1;0.216</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>=0.97</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ANG&#x02010;2</td><td align="left" rowspan="1" colspan="1">1.140&#x000b1;0.592</td><td align="left" rowspan="1" colspan="1">0.642&#x000b1;0.216</td><td align="left" rowspan="1" colspan="1">1.47&#x000b1;0.381</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>=0.06</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">FGF&#x02010;2</td><td align="left" rowspan="1" colspan="1">0.337&#x000b1;0.110</td><td align="left" rowspan="1" colspan="1">0.344&#x000b1;0.082</td><td align="left" rowspan="1" colspan="1">0.243&#x000b1;0.040</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>=0.46</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">PDGF&#x02010;BB</td><td align="left" rowspan="1" colspan="1">0.918&#x000b1;0.362</td><td align="left" rowspan="1" colspan="1">0.648&#x000b1;0.131</td><td align="left" rowspan="1" colspan="1">0.809&#x000b1;0.309</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>=0.65</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">VEGF</td><td align="left" rowspan="1" colspan="1">0.063&#x000b1;0.017</td><td align="left" rowspan="1" colspan="1">0.087&#x000b1;0.037</td><td align="left" rowspan="1" colspan="1">0.083&#x000b1;0.015</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>=0.20</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">IGF&#x02010;1</td><td align="left" rowspan="1" colspan="1">0.015&#x000b1;0.008</td><td align="left" rowspan="1" colspan="1">0.006&#x000b1;0.002</td><td align="left" rowspan="1" colspan="1">0.016&#x000b1;0.007</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>=0.81</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">HGF</td><td align="left" rowspan="1" colspan="1">0.007&#x000b1;0.004</td><td align="left" rowspan="1" colspan="1">0.007&#x000b1;0.003</td><td align="left" rowspan="1" colspan="1">0.031&#x000b1;0.008</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>&#x0003c;0.05<xref ref-type="fn" rid="jah31429-note-0003">*</xref>
<sup>,</sup>
<xref ref-type="fn" rid="jah31429-note-0003">&#x02020;</xref>
</td></tr></tbody></table><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">ELISA</th><th align="left" valign="top" rowspan="1" colspan="1">ICMP (n=15)</th><th align="left" valign="top" rowspan="1" colspan="1">CON (n=9)</th><th align="left" valign="top" rowspan="1" colspan="1">ACON (n=15)</th><th align="left" valign="top" rowspan="1" colspan="1">1&#x02010;Way ANOVA</th><th align="left" valign="top" rowspan="1" colspan="1">HCAEC Reference (n=3)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">hPLGF (pg/10<sup>6</sup> cells)</td><td align="left" rowspan="1" colspan="1">5772&#x000b1;1525</td><td align="left" rowspan="1" colspan="1">6133&#x000b1;1475</td><td align="left" rowspan="1" colspan="1">2767&#x000b1;368</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>=0.13</td><td align="left" rowspan="1" colspan="1">2326&#x000b1;579</td></tr><tr><td align="left" rowspan="1" colspan="1">hANG&#x02010;2 (ng/10<sup>6</sup> cells)</td><td align="left" rowspan="1" colspan="1">140&#x000b1;31</td><td align="left" rowspan="1" colspan="1">96&#x000b1;18</td><td align="left" rowspan="1" colspan="1">83&#x000b1;11</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>=0.66</td><td align="left" rowspan="1" colspan="1">12&#x000b1;4</td></tr><tr><td align="left" rowspan="1" colspan="1">hFGF (pg/10<sup>6</sup> cells)</td><td align="left" rowspan="1" colspan="1">965&#x000b1;730</td><td align="left" rowspan="1" colspan="1">439&#x000b1;160</td><td align="left" rowspan="1" colspan="1">56&#x000b1;8</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>&#x0003c;0.05<xref ref-type="fn" rid="jah31429-note-0003">*</xref>
<sup>,</sup>
<xref ref-type="fn" rid="jah31429-note-0003">&#x02020;</xref>
</td><td align="left" rowspan="1" colspan="1">133&#x000b1;54</td></tr><tr><td align="left" rowspan="1" colspan="1">hPDGF&#x02010;BB (pg/10<sup>6</sup> cells)</td><td align="left" rowspan="1" colspan="1">170&#x000b1;50</td><td align="left" rowspan="1" colspan="1">184&#x000b1;90</td><td align="left" rowspan="1" colspan="1">37&#x000b1;8</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>=0.04</td><td align="left" rowspan="1" colspan="1">20&#x000b1;8</td></tr></tbody></table><table-wrap-foot><fn id="jah31429-note-0002"><p>ANG&#x02010;1, EGF, HGF, IGF1, and VEGF below detection limit of the assay. All transcriptional results are expressed as a 2<sup>&#x02212;&#x00394;CT</sup>&#x02010;value, relative to <italic>HPRT</italic> as the housekeeping gene. ACON indicates age&#x02010;matched controls; ANG&#x02010;1/2, angiopoietin&#x02010;1/2; BOEC(s), blood outgrowth endothelial cell(s); CON, healthy young controls; FGF, fibroblast growth factor; HCAEC, human coronary artery endothelial cells; HGF, hepatocyte growth factor; ICMP, ischemic cardiomyopathy patients; IGF&#x02010;1, insulin&#x02010;like growth factor 1; NOS&#x02010;3, nitric oxide synthase 3; PDGF&#x02010;BB, platelet&#x02010;derived growth factor&#x02010;BB; PLGF, placental growth factor; RT&#x02010;qPCR, reverse&#x02010;transcriptase polymerase chain reaction; VEGF, vascular endothelial growth factor; vWF, von Willebrand factor.</p></fn><fn id="jah31429-note-0003"><p>One&#x02010;way ANOVA post&#x02010;test comparison: *<italic>P</italic>&#x0003c;0.05: ICMP vs ACON; <sup>&#x02020;</sup>CON vs ACON.</p></fn></table-wrap-foot></table-wrap></sec><sec id="jah31429-sec-0009"><title>Proliferation Potential</title><p>Cell numbers were calculated at every passage in order to derive expansion curves and calculate population doubling times throughout the entire expansion process. In addition to growth kinetics, senescence was quantified by senescence&#x02010;associated &#x003b2;&#x02010;galactosidase staining (Senescence Detection Kit; BioVision, Inc., Milpitas, CA). The number of blue cells was manually counted and reported as a percentage of the entire cell population.</p></sec><sec id="jah31429-sec-0010"><title>In Vitro Oxidative Stress</title><p>Production of reactive oxygen species (ROS) was quantified using CM&#x02010;H<sub>2</sub>DCFDA (Molecular Probes, Eugene, OR) as a fluorescent ROS indicator (Ex/Em: 492&#x02010;495/517&#x02010;527). Cells were loaded with a final dye concentration of 10&#x000a0;&#x003bc;mol/L for 30&#x000a0;minutes at 37&#x000b0;C. Intensity of the fluorescence was measured using a fluorescence plate reader at baseline, 10 and 45&#x000a0;minutes after exposure to 500&#x000a0;&#x003bc;mol/L H<sub>2</sub>O<sub>2</sub>. Additionally, cells were exposed to 1000&#x000a0;&#x003bc;mol/L of H<sub>2</sub>O<sub>2</sub> for 24&#x000a0;hours, after which cell viability was quantified by flow cytometry using 7&#x02010;aminoactinomycin D (7&#x02010;AAD) as a viability marker.</p></sec><sec id="jah31429-sec-0011"><title>In Vitro Neovascularization Potential</title><p>In a matrigel &#x0201c;network remodeling&#x0201d; (Tube Formation) assay (BD Matrigel Basement Membrane Matrix, 354234; BD Biosciences), a total of 75&#x000a0;000 BOECs were seeded per 24&#x02010;well, coated with 300&#x000a0;&#x003bc;L of Matrigel. Phase contrast mosaic images were acquired of the complete well after 6&#x000a0;hours of incubation. The cellular network was manually delineated in order to semiautomatically quantify total network length and the number of intersections using ImageJ software (National Institutes of Health, Bethesda, MD). Additionally, sprouting angiogenesis was studied using a three&#x02010;dimensional (3D) spheroid sprouting assay in collagen gel, as previously described with minor modifications.<xref rid="jah31429-bib-0016" ref-type="ref">16</xref> In short, BOEC spheroids containing 1000 cells were generated by suspension culture in EBM<sub>2</sub> culture medium containing 0.25% (w/v) carboxymethylcellulose, seeded in nonadherent round&#x02010;bottomed 96&#x02010;well plates. Under these conditions, all suspended cells contribute to the formation of a single BOEC spheroid per well. These spheroids were harvested within 24&#x000a0;hours and embedded in collagen gels (Rat Tail Collagen Type I; Corning, Corning, NY), as previously described.<xref rid="jah31429-bib-0016" ref-type="ref">16</xref> The length of the 3 longest capillary&#x02010;like sprouts that had grown out of each spheroid was measured after 24&#x000a0;hours. A total of 20&#x000b1;2 spheroids per sample were analyzed.</p></sec><sec id="jah31429-sec-0012"><title>In Vivo Neovascularization Potential</title><p>All animal procedures were approved by the Ethics Committee on Animal Use of KU Leuven (Leuven, Belgium) and conform to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health. Female 8&#x02010; to 10&#x02010;week&#x02010;old athymic NMRI nude mice (Janvier Labs, Le Genest&#x02010;Saint&#x02010;Isle, France) were anesthetized with an intraperitoneal injection of ketamine (100&#x000a0;mg/kg) and xylazine (15&#x000a0;mg/kg). The common, superficial, and deep femoral artery of the right leg were ligated and transsected in between. Laser Doppler measurements (PIM&#x02010;II; Lisca Development AB, Link&#x000f6;ping, Sweden) were performed under 2% isoflurane gas anesthesia and temperature&#x02010;controlled conditions (37&#x000b0;C) 5&#x000a0;days after hindlimb ischemia surgery to assess degree of flow reduction. Only animals with &#x02265;55% flow reduction in the ischemic versus nonligated control limb were included in the study.</p><p>Intramuscular injections of 250&#x000a0;000 BOECs from patients (ICMP) or young controls (CON) versus vehicle control (PBS) were performed in the ischemic hindlimb, 5&#x000a0;days after the ligation procedure. Cells were resuspended in 100&#x000a0;&#x003bc;L of PBS and subsequently injected into the thigh region (5&#x000d7;10&#x000a0;&#x003bc;L) and gastrocnemius muscle (5&#x000d7;10&#x000a0;&#x003bc;L) using a 1&#x02010;mL 29G syringe. Intraperitoneal anti&#x02010;asialo&#x02010;GM1 injections (Wako Chemicals, Inc., Dallas, TX) were performed once a week to suppress residual natural killer cell activity.</p><p>Mice were euthanized 21&#x000a0;days after femoral artery ligation. At sacrifice, mice were sedated with an intraperitoneal injection of Nembutal 70&#x000a0;mg/kg. A midline sternotomy was performed to expose the heart, followed by insertion of a winged 25G needle (Mycroflex; Vygon, Ecouen, France) into the LV apex and removal of the right auriculum. Vessels were perfused by the LV cavity with 20&#x000a0;mL of saline, containing 100&#x000a0;IU/mL of unfractionated heparin, in order to remove the blood and prevent clotting. Tissue was subsequently fixed by a 15&#x02010;mL perfusion with neutral buffered formalin 10%, followed by 20&#x000a0;mL of saline to wash out the fixative. A final perfusion with a preheated mixture of 30% barium sulphate (Micropaque; Guerbet, France) and 2% gelatin was performed in order to visualize the vessel tree on post&#x02010;mortem angio microCT (computed tomography). Mice were stored on ice overnight to solidify the gelatin and fix the contrast agent in the vessels.</p><p>The hind limbs were scanned with a high&#x02010;resolution microCT (50&#x000a0;kV, 200&#x000a0;&#x003bc;A, 10&#x000a0;W; SkyScan&#x02010;1172; SkyScan, Virginia Beach, VA) at a pixel size of 8&#x000a0;&#x003bc;m, providing highly detailed, quantitative 3D structural data of the perfused &#x0201c;vessel tree&#x0201d; of the complete limb. The individual two&#x02010;dimensional (2D) images were reconstructed into a 3D data set with isotropic voxel size of 8&#x000a0;&#x003bc;m using the manufacturer's dedicated software (NRecon; SkyScan). Analysis was performed using in&#x02010;house developed custom&#x02010;made software (MeVisLab based; MeVis Medical Solutions AG, Bremen, Germany) after an additional downsampling step by a factor of 4, for reasons of computational feasibility. The 3D vessel tree was automatically segmented for semiautomatic quantification. Data in the ligated leg were analyzed versus the nonligated control leg.</p></sec><sec id="jah31429-sec-0013"><title>Histology: <italic>Arthrobacter luteus</italic> Repeats and Combined hCD31/BS&#x02010;I Lectin Staining</title><p>Adductor and gastrocnemius muscles, as well as lung, spleen, liver, kidney and heart on a separate set of animals not perfused with gelatin/barium&#x02010;sulfate were collected and paraffin&#x02010;embedded to study BOEC incorporation and biodistribution. BOEC&#x02010;incorporation into the vasculature of adductor and gastrocnemius muscles, was studied by combined chromogenic in&#x000a0;situ hybridization for <italic>Arthrobacter luteus</italic> (ALU)&#x02010;repeats (ALU Positive Control Probe&#x02010;II and ISHiVIEW Blue Plus Detection Kit; Ventana Medical Systems, Inc., Oro Valley, AZ), as the primate&#x02010;specific sequence, and dual immunofluorescence staining for human (h) CD31 (anti&#x02010;hCD31 IgG<sub>1,&#x003ba;</sub>, m0823; Dako, Carpinteria, CA) and BS&#x02010;I Lectin (L3759; Sigma&#x02010;Aldrich) on adjacent sections. An initial acute retention and biodistribution study was performed, 24&#x000a0;hours after intramuscular injections (6&#x000a0;days after ligation) of 250&#x000a0;000 BOECs labeled by lentiviral overexpression of Cherry fluorescent protein. Moreover, chronic engraftment was quantified at 21&#x000a0;days.</p></sec><sec id="jah31429-sec-0014"><title>Statistical Analysis</title><p>All data are presented as mean&#x000b1;SEM. Intergroup differences were analyzed using 2&#x02010;tailed unpaired <italic>t</italic> tests or 1&#x02010;way ANOVA followed by a Bonferroni post&#x02010;hoc test for normally distributed data. Non&#x02010;normally distributed data were compared using a&#x000a0;nonparametric Mann&#x02013;Whitney test or nonparametric Kruskal&#x02013;Wallis test followed by Dunn's post&#x02010;hoc test. Pearson correlations were performed to analyze linear covariation between normally distributed data sets, whereas Spearman nonparametric correlation was performed for nonparametric datasets. A probability value of <italic>P</italic>&#x0003c;0.05 was considered statistically significant. All analyses were performed using Prism 5.0a software (version 5.0a; GraphPad Software Inc., La Jolla, CA).</p></sec></sec><sec id="jah31429-sec-0015"><title>Results</title><sec id="jah31429-sec-0016"><title>Patient Characteristics</title><p>BOEC isolations were performed in 45 patients (ICMP, 66&#x000b1;1&#x000a0;years) and 32 healthy age&#x02010;matched (ACON, 60&#x000b1;1&#x000a0;years) and 55 healthy young (CON, 34&#x000b1;1&#x000a0;years) controls (Table&#x000a0;<xref rid="jah31429-tbl-0001" ref-type="table-wrap">1</xref>). Global systolic LV function was impaired (LVEF 31&#x000b1;2%) without concomitant adverse LV remodeling (left ventricular end diastolic diameter [LVEDD], 56&#x000b1;1&#x000a0;mm) in the majority of patients. Adverse LV remodeling, defined as an LVEDD &#x02265;60&#x000a0;mm on a transthoracic acquired echocardiography parasternal long axis view, was present in 12 of 45 (26.7%) patients. Four patients were excluded from the study because blood was taken less than 1&#x000a0;month after device implantation.</p></sec><sec id="jah31429-sec-0017"><title>BOEC Outgrowth Efficiency</title><p>Starting from 40 to 60&#x000a0;mL of whole blood, a mean of 3.6&#x000b1;0.6 BOEC colonies/100&#x000d7;10<sup>6</sup> MNCs could be obtained from patients versus 3.5&#x000b1;0.9 from age&#x02010;matched controls and 2.6&#x000b1;0.4 from healthy young controls (<italic>P</italic>=0.29; Figure&#x000a0;<xref rid="jah31429-fig-0002" ref-type="fig">2</xref>A). Colonies could be obtained in 84% of ICMP, 72% of ACON and 82% of CON. The number of BOEC colonies obtained in our ICMP population increased with age (<italic>r</italic>=0.42; <italic>P</italic>&#x0003c;0.01; Figure&#x000a0;<xref rid="jah31429-fig-0002" ref-type="fig">2</xref>B), but was not affected by severity of the disease process, assessed by LVEF (<italic>r</italic>=&#x02212;0.12; Figure&#x000a0;<xref rid="jah31429-fig-0002" ref-type="fig">2</xref>C) or adverse LV remodeling (Figure&#x000a0;<xref rid="jah31429-fig-0002" ref-type="fig">2</xref>D). BOEC outgrowth was independent of the extent of coronary artery disease, number of cardiovascular risk factors, and presence of diabetes mellitus (Figure&#x000a0;<xref rid="jah31429-fig-0002" ref-type="fig">2</xref>E through <xref rid="jah31429-fig-0002" ref-type="fig">2</xref>G).</p><fig fig-type="Figure" xml:lang="en" id="jah31429-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>BOEC outgrowth characteristics. BOECs can be isolated to the same extent from patients and controls (A), irrespective of age (B), severity of the disease process (C, D, and E), and cardiovascular risk factors (F and G). The linear regression line is surrounded by 95% confidence bands (C). 1/2/3&#x02010;VD indicates 1/2/3&#x02010;vessel disease; ACON, age&#x02010;matched controls; CON, healthy young controls; CVRF, cardiovascular risk factors; DM, diabetes mellitus; ICMP, ischemic cardiomyopathy patients; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; y, years.</p></caption><graphic id="nlm-graphic-3" xlink:href="JAH3-5-e002288-g002"/></fig></sec><sec id="jah31429-sec-0018"><title>BOEC Phenotype</title><p>BOECs uniformly expressed CD31, bound lectin, and took up Dil&#x02010;AcLDL (representative examples are shown in Figure&#x000a0;<xref rid="jah31429-fig-0003" ref-type="fig">3</xref>A through <xref rid="jah31429-fig-0003" ref-type="fig">3</xref>C). Flow cytometry evaluation of endothelial (CD31<sup>+</sup>, CD309<sup>+</sup>, and CD146<sup>+</sup>) and progenitor (CD34<sup>+</sup>, CD133<sup>&#x02212;</sup>) cell surface markers did not differ between groups (Figure&#x000a0;<xref rid="jah31429-fig-0003" ref-type="fig">3</xref>D). The panleukocyte marker, CD45, was absent in all groups. RT&#x02010;qPCR neither showed differences in expression for additional endothelial markers, such as <italic>VWF</italic> and <italic>NOS3</italic> (Table&#x000a0;<xref rid="jah31429-tbl-0002" ref-type="table-wrap">2</xref>, top).</p><fig fig-type="Figure" xml:lang="en" id="jah31429-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>BOEC phenotype. BOECs display the typical cobblestone morphology (A) (scale bar, 200&#x000a0;&#x003bc;m), stain positive for UEA&#x02010;lectin and the endothelial marker, CD31 (B) (scale bar, 20&#x000a0;&#x003bc;m), and take up acetylated LDL (C) (scale bar, 20&#x000a0;&#x003bc;m). Representative flow cytometry analysis (D) for endothelial markers (CD31<sup>+</sup>/CD309<sup>+</sup>/CD146<sup>+</sup>), progenitor markers (CD34<sup>+</sup>/CD133<sup>&#x02212;</sup>), and a panleukocytic marker (CD45<sup>&#x02212;</sup>) on ICMP&#x02010;BOECs. Flow cytometry data (red line in histogram) are expressed in relation to respective isotype controls (black line in histogram) and a quantitative comparison with CON&#x02010;BOECs is shown in the table. BOEC indicates blood outgrowth endothelial cell; CON, healthy young controls; DAPI, 4&#x02019;,6&#x02010;diamidino&#x02010;2&#x02010;phenylindole; ICMP, ischemic cardiomyopathy patients; LDL, low&#x02010;density lipoprotein; UAE, <italic>Ulex europeus</italic> agglutinin.</p></caption><graphic id="nlm-graphic-5" xlink:href="JAH3-5-e002288-g003"/></fig></sec><sec id="jah31429-sec-0019"><title>BOEC Proliferation Potential</title><p>We aimed to expand our cells to a target dose of &#x02248;30&#x000d7;10<sup>6</sup> BOECs from 60&#x000a0;mL of whole blood, a cell number with proven functional benefit in our porcine myocardial ischemia/reperfusion model.<xref rid="jah31429-bib-0007" ref-type="ref">7</xref> Proliferation potential, studied by growth kinetics and senescence&#x02010;associated &#x003b2;&#x02010;galactosidase staining, did not show differences between BOECs from ICMP and (A)CON. Population doubling times (<italic>P</italic>=0.16) and slopes of the log<sub>10</sub>(expansion curves) (<italic>P</italic>=0.38) showed comparable growth kinetics (Figure&#x000a0;<xref rid="jah31429-fig-0004" ref-type="fig">4</xref>A). The number of senescent cells was 5.8&#x000b1;2.1% in ICMP (n=17) versus 3.9&#x000b1;1.1% and 9.0&#x000b1;2.8% of total BOECs in ACON (n=7) and CON (n=13), respectively (<italic>P</italic>=0.19; Figure&#x000a0;<xref rid="jah31429-fig-0004" ref-type="fig">4</xref>B). Starting from a single 60&#x02010;mL blood sample in our patient population, expansion up to 30&#x000d7;10<sup>6</sup> BOECs was achieved in 52% of isolations, if initial BOEC colonies were obtained. The number of initial BOEC colonies (<italic>P</italic>&#x0003c;0.0001) and the time of appearance of the first clone (<italic>P</italic>=0.005) were major predictors of expansion success. If expansion up to 30&#x000d7;10<sup>6</sup> cells could be achieved, the average number of BOEC colonies to start from was 9.9&#x000b1;2.3/isolation with an appearance at day 12&#x000b1;1. In contrast, if expansion up to 30&#x000d7;10<sup>6</sup> cells failed, on average only 2.5&#x000b1;0.5 colonies/isolation were initially obtained with an appearance at day 16&#x000b1;1. Clinical, biochemical, or hematological predictors of expansion potential could not be identified.</p><fig fig-type="Figure" xml:lang="en" id="jah31429-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>BOEC expansion potential. Growth kinetics, studied by population doubling times (A3) and the slope of the log<sub>10</sub>(expansion curves) (A1,2), showed similar proliferation rates in BOECs from ICMP patients and controls. Growth kinetics were studied from the start of the polyclonal phase, defined as day 0, the time point at which individual BOEC colonies were picked and pooled for culture expansion. The number of senescent cells, quantified as the percentage of blue cells in the senescence&#x02010;associated &#x003b2;&#x02010;galactosidase staining (B1) (scale bar, 200&#x000a0;&#x003bc;m), did not differ between patients and controls (B2). ACON indicates age&#x02010;matched controls; BOEC, blood outgrowth endothelial cell; CON, healthy young controls; ICMP, ischemic cardiomyopathy patients.</p></caption><graphic id="nlm-graphic-7" xlink:href="JAH3-5-e002288-g004"/></fig></sec><sec id="jah31429-sec-0020"><title>BOEC Response to Oxidative Stress</title><p>No differences were noted in baseline reactive oxygen species (ROS) production in BOECs isolated from ICMP (n=5) and CON (n=6; <italic>P</italic>=0.37; Figure&#x000a0;<xref rid="jah31429-fig-0005" ref-type="fig">5</xref>A). Moreover, induction by 500&#x000a0;&#x003bc;mol/L of H<sub>2</sub>O<sub>2</sub> showed comparable increase in ROS production in ICMP and CON, 10 and 45&#x000a0;minutes after exposure (<italic>P</italic>=0.60; Figure&#x000a0;<xref rid="jah31429-fig-0005" ref-type="fig">5</xref>A). Additionally, 24&#x000a0;hours of exposure to 1000&#x000a0;&#x003bc;mol/L of H<sub>2</sub>O<sub>2</sub> did not show significant differences in BOEC viability between ICMP (n=6) and CON (n=6; <italic>P</italic>=0.11; Figure&#x000a0;<xref rid="jah31429-fig-0005" ref-type="fig">5</xref>B).</p><fig fig-type="Figure" xml:lang="en" id="jah31429-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>BOEC response to oxidative stress: ROS production was quantified using CM&#x02010;H<sub>2</sub>DCFDA as a fluorescent ROS indicator. No differences were noted in baseline ROS production in BOECs isolated from ICMP and CON (A). Moreover, induction by 500&#x000a0;&#x003bc;mol/L of H<sub>2</sub>O<sub>2</sub> showed a similar increase in ROS production in ICMP and CON (A). Additionally, 24&#x000a0;hours of exposure to 1000&#x000a0;&#x003bc;mol/L of H<sub>2</sub>O<sub>2</sub> did not show significant differences in BOEC viability between ICMP and CON, quantified by flow cytometry using 7&#x02010;AAD as a viability marker (B). 2&#x02010;way RM ANOVA indicates 2&#x02010;way repeated&#x02010;measures ANOVA; 7&#x02010;AAD, 7&#x02010;aminoactinomycin D; BOEC, blood outgrowth endothelial cell; CON, healthy young controls; ICMP, ischemic cardiomyopathy patients; ROS, reactive oxygen species.</p></caption><graphic id="nlm-graphic-9" xlink:href="JAH3-5-e002288-g005"/></fig></sec><sec id="jah31429-sec-0021"><title>BOEC In Vitro Neovascularization Potential</title><p>We subsequently focused on functional neovascularization potential of the obtained cell populations. In vitro vasculogenic potential, explored using the Matrigel network remodeling assay (Figure&#x000a0;<xref rid="jah31429-fig-0006" ref-type="fig">6</xref>A), did not show differences in the number of network intersections between cells from ICMP and (A)CON (<italic>P</italic>=0.32; Figure&#x000a0;<xref rid="jah31429-fig-0006" ref-type="fig">6</xref>B). Total network length did not differ between cells from ICMP and (A)CON. An increase in network length was, however, noted in aged versus young controls. Severity of the disease process, assessed by LVEF, did not impair in&#x000a0;vitro network formation potential. On the contrary, LVEF inversely correlated with total network length (<italic>r</italic>=&#x02212;0.57; <italic>P</italic>=0.01; n=16) and the number of intersections (<italic>r</italic>=&#x02212;0.53; <italic>P</italic>=0.03; n=16; Figure&#x000a0;<xref rid="jah31429-fig-0006" ref-type="fig">6</xref>C). Body mass index (BMI) was positively correlated with in&#x000a0;vitro vasculogenic potential (<italic>r</italic>=0.58; <italic>P</italic>=0.02; n=16). No other major clinical, biochemical, or hematological predictors could be identified. Additionally, in&#x000a0;vitro angiogenesis potential, explored using a 3D spheroid sprouting assay in collagen gel, did not show differences in sprouting angiogenesis between BOECs from ICMP and CON (<italic>P</italic>=0.70; Figure&#x000a0;<xref rid="jah31429-fig-0007" ref-type="fig">7</xref>).</p><fig fig-type="Figure" xml:lang="en" id="jah31429-fig-0006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>BOEC Matrigel network formation potential. Network remodeling was photographed using phase&#x02010;contrast mosaic acquisition (A, top panel) and subsequently manually delineated (A, lower panel&#x02014;network delineation in red) in order to quantify total network length and the number of intersections (scale bar, 1000&#x000a0;&#x003bc;m). Total network length (B1) and the number of intersections (B2) in patients did not differ from controls. Severity of the disease process, assessed by left ventricular ejection fraction (LVEF), did not compromise in&#x000a0;vitro network formation potential (C1,2). Linear regression lines are surrounded by 95% confidence bands (C1,2). ACON indicates age&#x02010;matched controls; BOEC, blood outgrowth endothelial cell; CON, healthy young controls; ICMP, ischemic cardiomyopathy patients.</p></caption><graphic id="nlm-graphic-11" xlink:href="JAH3-5-e002288-g006"/></fig><fig fig-type="Figure" xml:lang="en" id="jah31429-fig-0007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>BOEC 3D spheroid sprouting assay: BOEC spheroids, containing 1000 cells, were embedded into collagen gels. The length of the 3 longest capillary&#x02010;like sprouts that had grown out of each spheroid was measured after 24&#x000a0;hours. No differences were noted in average sprout length between ICMP and CON (A). Representative images of sprouting BOEC spheroids from ICMP (B) and CON (C) (scale bar, 200&#x000a0;&#x003bc;m). 3D indicates three&#x02010;dimensional; BOEC, blood outgrowth endothelial cell; CON indicates healthy young controls; ICMP, ischemic cardiomyopathy patients.</p></caption><graphic id="nlm-graphic-13" xlink:href="JAH3-5-e002288-g007"/></fig><p>RTqPCR and ELISA documented a marked proangiogenic profile with high expression of angiogenic growth factors (ANG&#x02010;2, PLGF, PDGF&#x02010;BB, FGF&#x02010;2, and VEGF) both in BOECs from patients and controls (Table&#x000a0;<xref rid="jah31429-tbl-0002" ref-type="table-wrap">2</xref>). ANG&#x02010;2 and PLGF were the most abundant angiogenic growth factors in 24&#x02010;hour conditioned medium, with similar amounts secreted by BOECs from ICMP and healthy subjects ([A]CON) (<italic>P</italic>=0.66 and 0.13 for ANG&#x02010;2 and PLGF, respectively).</p></sec><sec id="jah31429-sec-0022"><title>BOEC In Vivo Neovascularization Potential</title><p>Initial acute retention and biodistribution studies, using Cherry&#x02010;labeled BOECs, documented multiple clusters and singlets of transplanted cells in the femoral and tibiofibular region 24&#x000a0;hours after intramuscular cell delivery (average of 312 BOECs/4.5&#x000a0;mm<sup>2</sup>), mainly localized in perimuscular connective tissue (Figure&#x000a0;<xref rid="jah31429-fig-0008" ref-type="fig">8</xref>). No detectable distribution was observed in lungs, spleen, liver, kidneys, and heart.</p><fig fig-type="Figure" xml:lang="en" id="jah31429-fig-0008" orientation="portrait" position="float"><label>Figure 8</label><caption><p>Acute BOEC retention. Confocal microscopy documents multiple clusters (A1) and singlets (A2) of Cherry&#x02010;labeled BOECs (red), 24&#x000a0;hours after intramuscular injection into the ischemic hindlimb. These findings were confirmed by immunofluorescence microscopy for human CD31 (red; labeling only transplanted cells) and BS&#x02010;I&#x02010;Lectin (green; labeling host endothelium) (B1) and in&#x000a0;situ hybridization for primate&#x02010;specific ALU&#x02010;repeat sequences (dark blue) on the respective adjacent slides (B2) (scale bar, 100&#x000a0;&#x003bc;m). Clusters and singlets of human BOECs are indicated by white arrows. ALU indicates <italic>Arthrobacter luteus</italic>; BOEC(s), blood outgrowth endothelial cell(s); CON indicates healthy young controls; ICMP, ischemic cardiomyopathy patients.</p></caption><graphic id="nlm-graphic-15" xlink:href="JAH3-5-e002288-g008"/></fig><p>Doppler flow index at inclusion (5&#x000a0;days after hindlimb ischemia surgery) was similar in all groups (vehicle control: 35.9&#x000b1;1.5; CON&#x02010;BOECs: 35.5&#x000b1;1.8; ICMP&#x02010;BOECs: 35.9&#x000b1;2.0; <italic>P</italic>=0.98). High&#x02010;resolution angio microCT of the upper leg confirmed enhanced BOEC&#x02010;mediated arteriogenesis in comparison to vehicle control, 21&#x000a0;days after surgery (Figure&#x000a0;<xref rid="jah31429-fig-0009" ref-type="fig">9</xref>). Although total vessel length and the number of vessel branch points tended to be increased after BOEC delivery from both CON and ICMP (Figure&#x000a0;<xref rid="jah31429-fig-0009" ref-type="fig">9</xref>B), therapeutic effects were confined to smaller arterioles with a diameter ranging from 32 to 64&#x000a0;&#x003bc;m (Figure&#x000a0;<xref rid="jah31429-fig-0009" ref-type="fig">9</xref>D), corresponding to collateral arteries, as documented by Scholz and Schaper.<xref rid="jah31429-bib-0017" ref-type="ref">17</xref>, <xref rid="jah31429-bib-0018" ref-type="ref">18</xref> Importantly, increased arteriogenesis was observed after transplantation of BOECs from healthy young controls (<italic>P</italic>=0.048) and ICMP patients (<italic>P</italic>=0.025) over vehicle control, both to a similar extent (<italic>P</italic>=0.831). Clinically, BOECs were able to prevent additional amputations after cell delivery (5&#x000a0;days after hindlimb ischemia surgery). A total of 3 of 14 animals suffered from additional amputations after injections of vehicle control versus none in the BOEC&#x02010;injected groups.</p><fig fig-type="Figure" xml:lang="en" id="jah31429-fig-0009" orientation="portrait" position="float"><label>Figure 9</label><caption><p>In vivo neovascularization potential assessed by angio microCT: Representative 3D reconstructions (left panel) and quantitative analysis (right panel). Representative 3D angio microCT reconstructions illustrate an enhanced neovascularization response in the thigh region after intramuscular injections of BOECs from both patients (ICMP) and CON (A). Twenty&#x02010;one days after hindlimb ischemia surgery, angio microCT quantifications documented a trend toward increased vessel length (B1) and number of vessel branch points (B2) in the thigh region (A and C) after intramuscular BOEC injections of patients (ICMP) and CON in comparison to vehicle control (PBS). BOEC&#x02010;mediated effects were confined to arterioles 32 to 64&#x000a0;&#x003bc;m in diameter (2&#x02010;tailed unpaired <italic>t</italic> tests) (D). All results from the ischemic hindlimb (HLI) are expressed in relation to the contralateral control leg (CONT). 3D indicates three&#x02010;dimensional; BOEC, blood outgrowth endothelial cell; CON indicates healthy young controls; CT, computed tomography; ICMP, ischemic cardiomyopathy patients; ROI, region of interest.</p></caption><graphic id="nlm-graphic-17" xlink:href="JAH3-5-e002288-g009"/></fig><p>Immunostaining for human CD31 and in&#x000a0;situ hybridization for primate specific ALU&#x02010;repeat sequences could detect incorporation of rare human BOECs into murine vessels in the ischemic hindlimb 21&#x000a0;days after surgery (Figure&#x000a0;<xref rid="jah31429-fig-0010" ref-type="fig">10</xref>). Engraftment, studied in 3 versus 3 mice, showed 4&#x000b1;2 incorporated ICMP&#x02010;BOECs/4.5&#x000a0;mm<sup>2</sup> versus 3&#x000b1;2 incorporated CON&#x02010;BOECs/4.5&#x000a0;mm<sup>2</sup>. This limited incorporation after&#x000a0;injection of 250&#x000a0;000 BOECs/mouse suggests a concomitant paracrine contribution of the transplanted cell&#x000a0;population to their documented neovascularization potential.<xref rid="jah31429-bib-0007" ref-type="ref">7</xref>, <xref rid="jah31429-bib-0008" ref-type="ref">8</xref>
</p><fig fig-type="Figure" xml:lang="en" id="jah31429-fig-0010" orientation="portrait" position="float"><label>Figure 10</label><caption><p>Human BOECs incorporate into murine blood vessels. Immunofluorescence costaining for human CD31 (A1,B1), BS&#x02010;I&#x02010;Lectin (A2,B2), and DAPI nuclear counterstain (A3,B3) demonstrates human BOEC incorporation (red) into murine blood vessels (green) in the adductor (A) and gastrocnemius (B) region, 21&#x000a0;days after hindlimb ischemia surgery (scale bar, 20&#x000a0;&#x003bc;m). These findings were confirmed by in&#x000a0;situ hybridization for primate&#x02010;specific ALU&#x02010;repeat sequences on adjacent slides, showing incorporated human BOECs in dark blue (A5,B5) (A5 scale bar, 100&#x000a0;&#x003bc;m; B5 scale bar, 50&#x000a0;&#x003bc;m). Field of view of the immunofluorescence images is indicated in red. Engrafted human BOECs are indicated by white arrows. ALU indicates <italic>Arthrobacter luteus</italic>; BOEC(s), blood outgrowth endothelial cell(s); DAPI, 4&#x02019;,6&#x02010;diamidino&#x02010;2&#x02010;phenylindole.</p></caption><graphic id="nlm-graphic-19" xlink:href="JAH3-5-e002288-g010"/></fig></sec></sec><sec id="jah31429-sec-0023"><title>Discussion</title><p>We report that BOECs can be successfully isolated and culture&#x02010;expanded from patients with severe, but stable, ischemic cardiomyopathy, irrespective of age, severity of myocardial systolic dysfunction, or degree of maladaptive LV remodeling. These cells show a robust and consistent endothelial progenitor phenotype with comparable proliferation kinetics and without evidence of increased senescence when compared to cells isolated from young or age&#x02010;matched healthy subjects. We did not document differences in in&#x000a0;vitro neovascularization potential of BOECs from patients or controls, because they form comparable vascular networks in Matrigel, demonstrate similar sprouting potential in a 3D spheroid&#x02010;sprouting angiogenesis assay, and secrete high levels of potent angiogenic and arteriogenic factors. After in&#x000a0;vivo cell transfer, BOECs from patients and healthy donors increase collateral vascular remodeling in the thigh region of nude mice, with significant induction of arterioles 32 to 64&#x000a0;&#x003bc;m in diameter and prevention of imminent amputations after cell delivery.</p><p>In contrast to various other EPC subtypes studied as biomarkers of cardiovascular risk and disease,<xref rid="jah31429-bib-0014" ref-type="ref">14</xref>, <xref rid="jah31429-bib-0019" ref-type="ref">19</xref> we did not observe inverse correlations between the number of BOEC outgrowth colonies and severity of the ischemic atherosclerotic disease process. We did not observe a disease&#x02010;related increase in the number of BOEC colonies obtained, as was previously shown during active inflammation, tissue damage, and intense vascular remodeling (acute myocardial infarction,<xref rid="jah31429-bib-0020" ref-type="ref">20</xref> acute ischemic stroke,<xref rid="jah31429-bib-0021" ref-type="ref">21</xref>, <xref rid="jah31429-bib-0022" ref-type="ref">22</xref> rheumatoid arthritis,<xref rid="jah31429-bib-0023" ref-type="ref">23</xref> neovascular age&#x02010;related macular degeneration,<xref rid="jah31429-bib-0024" ref-type="ref">24</xref> or extensive burns<xref rid="jah31429-bib-0025" ref-type="ref">25</xref>). In our patient population with stable ischemic heart failure, optimally treated according to current guidelines, a similar number of BOEC colonies were obtained in patients and healthy controls. These findings are consistent with earlier data in statin&#x02010;treated patients with premature coronary artery disease.<xref rid="jah31429-bib-0026" ref-type="ref">26</xref> Within our patient cohort, we did, however, note a mild positive correlation between age and BOEC outgrowth, absent in our control population.</p><p>Because of limited cell retention after intracoronary or intramyocardial delivery, a sufficient cell mass is needed to obtain therapeutic effects in the target region as previously shown in domestic swine.<xref rid="jah31429-bib-0007" ref-type="ref">7</xref> Starting from a single 60&#x02010;mL blood sample, we were able to achieve our expansion goal of 30&#x000d7;10<sup>6</sup> cells in 52% of patients, with similar growth kinetics in controls. Given that we showed expansion success to be highly dependent on the number of initial BOEC colonies obtained, increasing the number of MNCs by increasing the volume of the blood sample or using leukapheresis could further enhance expansion success.</p><p>In contrast to various other cell types, we observed preserved neovascularization potential of BOECs derived from an older patient population with severe ICMP. Ingram et&#x000a0;al. reported that BOECs contain a complete hierarchy of low&#x02010; and high&#x02010;proliferation potential cells, analogous to the hematopoietic cell system.<xref rid="jah31429-bib-0027" ref-type="ref">27</xref> Moreover, long&#x02010;term culture conditions may erase the functional &#x0201c;fingerprint&#x0201d; of various microenvironmental factors, present in the donor milieu. Cell types with a previously documented dysfunctional phenotype in an older patient population with ischemic heart disease were only exposed to short&#x02010;term in&#x000a0;vitro cell culture (eg, circulating angiogenic cells and colony&#x02010;forming&#x02010;unit EPCs) or no in&#x000a0;vitro environment at all (eg, CD133<sup>+</sup>/VEGFR2<sup>+</sup> circulating EPCs and bone&#x02010;marrow&#x02013;derived MNCs). Hence, &#x0201c;weaning off&#x0201d; donor microenvironmental influences and positive selection based on proliferation potential were only minimally or not present. Specific reports on BOEC functionality and proliferation potential in various other disease states are, however, not uniform. Functional impairment has been reported, related to age,<xref rid="jah31429-bib-0028" ref-type="ref">28</xref> type 2 diabetes,<xref rid="jah31429-bib-0029" ref-type="ref">29</xref> obesity,<xref rid="jah31429-bib-0030" ref-type="ref">30</xref> pulmonary arterial hypertension,<xref rid="jah31429-bib-0031" ref-type="ref">31</xref> and smoking/chronic obstructive pulmonary disease.<xref rid="jah31429-bib-0032" ref-type="ref">32</xref> On the other hand, previous reports in treated coronary artery disease<xref rid="jah31429-bib-0026" ref-type="ref">26</xref>, <xref rid="jah31429-bib-0033" ref-type="ref">33</xref>, <xref rid="jah31429-bib-0034" ref-type="ref">34</xref> and arterial hypertension<xref rid="jah31429-bib-0035" ref-type="ref">35</xref> documented similar BOEC functionality in comparison to&#x000a0;healthy controls. Moreover, improved BOEC functionality&#x000a0;has&#x000a0;been demonstrated in neovascular age&#x02010;related macular&#x000a0;degeneration,<xref rid="jah31429-bib-0024" ref-type="ref">24</xref> ischemic stroke,<xref rid="jah31429-bib-0022" ref-type="ref">22</xref> and extensive burns.<xref rid="jah31429-bib-0025" ref-type="ref">25</xref>, <xref rid="jah31429-bib-0026" ref-type="ref">26</xref>, <xref rid="jah31429-bib-0033" ref-type="ref">33</xref>, <xref rid="jah31429-bib-0034" ref-type="ref">34</xref>, <xref rid="jah31429-bib-0035" ref-type="ref">35</xref> In comparison to healthy controls, our findings did not demonstrate differences in BOEC functionality and proliferation potential in a patient population with severe, but stable, ischemic heart failure. We noted, however, mild positive correlations between Matrigel network formation potential and both degree of systolic LV dysfunction and BMI within our patient cohort. No differences were noted in response to oxidative stress, studied by ROS induction and cell viability.</p><p>We studied in&#x000a0;vivo cell&#x02010;mediated neovascularization potential using high&#x02010;resolution angio microCT because of its ability to quantitatively assess the complete &#x0201c;vessel tree&#x0201d; in 3D. Histology is mainly restricted to evaluating vascular density in a limited 2D area of view, whereas laser Doppler flowmetry is only reporting superficial blood flow (200&#x02013;300&#x000a0;&#x003bc;m penetration depth), classically in the foot region.<xref rid="jah31429-bib-0036" ref-type="ref">36</xref> Collateral vascular remodeling (arteriogenesis) has been postulated as the most important mechanism to compensate for bulk perfusion loss. Efficient collateral formation is a critical determinant of tissue vulnerability and preservation during ischemia. Occlusion of the femoral artery in a hindlimb ischemia model results in development of collateral vessels in the upper leg, relatively close to the site of occlusion. In contrast, ischemia and angiogenesis occur in the lower leg and foot.<xref rid="jah31429-bib-0037" ref-type="ref">37</xref> We consequently focused on the thigh region as the readout for collateral vascular remodeling, and observed that cells from both patients and controls support the arteriogenesis process to a similar extent, especially at the level of arterioles (32&#x02013;64&#x000a0;&#x003bc;m in diameter). Extensive (ultra)structural histological analysis by Scholz and Schaper in murine hindlimbs previously identified collateral arteries in the 40&#x02010; to 70&#x02010;&#x003bc;m diameter range.<xref rid="jah31429-bib-0017" ref-type="ref">17</xref>, <xref rid="jah31429-bib-0018" ref-type="ref">18</xref> We documented a significant BOEC&#x02010;mediated increase in vascular length within this specific size range. A&#x000a0;trend toward a BOEC&#x02010;mediated increase of vessel length and number of branch points of the complete vessel tree in the thigh region of the ligated leg was noted. These results did, however, not reach statistical significance, given that the therapeutic effects were confined to one specific size range (arterioles 32&#x02013;64&#x000a0;&#x003bc;m in diameter). Arteriogenesis relies on a complex interplay of many growth factors, of which ANG&#x02010;2, PLGF, FGF, and PDGF&#x02010;BB were all demonstrated to be secreted by BOECs.<xref rid="jah31429-bib-0037" ref-type="ref">37</xref>, <xref rid="jah31429-bib-0038" ref-type="ref">38</xref>, <xref rid="jah31429-bib-0039" ref-type="ref">39</xref>, <xref rid="jah31429-bib-0040" ref-type="ref">40</xref>
</p><p>Acute retention studies documented BOECs, mainly clustered within the perimuscular compartment 24&#x000a0;hours after intramuscular injection. At 21&#x000a0;days, we noted disappearance of the BOEC clusters in the perimuscular compartment and appearance of isolated BOECs in the vascular compartment. We observed only limited incorporation/engraftment of BOECs into functional blood vessels after intramuscular delivery of 250&#x000a0;000 cells per mouse, suggesting a concomitant paracrine contribution of the transplanted cell population to their neovascularization potential. These findings indicate migration toward and engraftment within the vascular compartment to perform their biological effects, &#x0201c;sustained&#x0201d; release of a proangiogenic/&#x02010;arteriogenic growth factor &#x0201c;cocktail&#x0201d; with or without incorporation into functional vessels. ANG&#x02010;2 and PLGF were found to be the most abundantly secreted angiogenic growth factors, independent of underlying ischemic disease. Both ANG&#x02010;2 and PLGF play an important role in the complex cytokine cocktail, mediating the overall neovascularization process in ischemic disease.<xref rid="jah31429-bib-0037" ref-type="ref">37</xref>, <xref rid="jah31429-bib-0038" ref-type="ref">38</xref>, <xref rid="jah31429-bib-0039" ref-type="ref">39</xref>, <xref rid="jah31429-bib-0040" ref-type="ref">40</xref>, <xref rid="jah31429-bib-0041" ref-type="ref">41</xref>, <xref rid="jah31429-bib-0042" ref-type="ref">42</xref>, <xref rid="jah31429-bib-0043" ref-type="ref">43</xref>, <xref rid="jah31429-bib-0044" ref-type="ref">44</xref>, <xref rid="jah31429-bib-0045" ref-type="ref">45</xref>, <xref rid="jah31429-bib-0046" ref-type="ref">46</xref>, <xref rid="jah31429-bib-0047" ref-type="ref">47</xref>
</p><p>In conclusion, we report that BOECs can be isolated and culture&#x02010;expanded from patients with severe, but stable, ICMP and offer an easily accessible, clonally expandable cell source with profound neovascularization potential. In contrast to impaired functionality of other progenitor cell types derived from patients with advanced cardiovascular disease, BOECs retain a robust proangiogenic profile in&#x000a0;vitro and in&#x000a0;vivo and hold promise for autologous cell therapy in severe or refractory ischemic heart disease.</p></sec><sec id="jah31429-sec-0024"><title>Sources of Funding</title><p>This work was supported by the Research Foundation Flanders (FWO), a KULeuven Research Grant (PF\10\014) and funds from the ISCIII (PI13/02144, CP09/00333). Nick van Gastel is funded by BOF&#x02010;KU Leuven GOA project 3M120209. Aernout Luttun is supported by an Interuniversity Attraction Poles (IUAP) grant (IUAP/P7/07).</p></sec><sec id="jah31429-sec-0025"><title>Disclosures</title><p>None.</p></sec></body><back><ref-list content-type="cited-references" id="jah31429-bibl-0001"><title>References</title><ref id="jah31429-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah31429-cit-0001">
<string-name>
<surname>Yoder</surname>
<given-names>MC</given-names>
</string-name>. <article-title>Defining human endothelial progenitor cells</article-title>. <source>J Thromb Haemost</source>. <year>2009</year>;<volume>7</volume>(<issue>suppl 1</issue>):<fpage>49</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">19630767</pub-id></mixed-citation></ref><ref id="jah31429-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah31429-cit-0002">
<string-name>
<surname>Hirschi</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Ingram</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Yoder</surname>
<given-names>MC</given-names>
</string-name>. <article-title>Assessing identity, phenotype, and fate of endothelial progenitor cells</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2008</year>;<volume>28</volume>:<fpage>1584</fpage>&#x02013;<lpage>1595</lpage>.<pub-id pub-id-type="pmid">18669889</pub-id></mixed-citation></ref><ref id="jah31429-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah31429-cit-0003">
<string-name>
<surname>Fadini</surname>
<given-names>GP</given-names>
</string-name>, <string-name>
<surname>Baesso</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Albiero</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sartore</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Agostini</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Avogaro</surname>
<given-names>A</given-names>
</string-name>. <article-title>Technical notes on endothelial progenitor cells: ways to escape from the knowledge plateau</article-title>. <source>Atherosclerosis</source>. <year>2008</year>;<volume>197</volume>:<fpage>496</fpage>&#x02013;<lpage>503</lpage>.<pub-id pub-id-type="pmid">18249408</pub-id></mixed-citation></ref><ref id="jah31429-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah31429-cit-0004">
<string-name>
<surname>Yoder</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Mead</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Prater</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Krier</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Mroueh</surname>
<given-names>KN</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Krasich</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Temm</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Prchal</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Ingram</surname>
<given-names>DA</given-names>
</string-name>. <article-title>Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals</article-title>. <source>Blood</source>. <year>2007</year>;<volume>109</volume>:<fpage>1801</fpage>&#x02013;<lpage>1809</lpage>.<pub-id pub-id-type="pmid">17053059</pub-id></mixed-citation></ref><ref id="jah31429-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah31429-cit-0005">
<string-name>
<surname>Mannheimer</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Camici</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Chester</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Collins</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>DeJongste</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Eliasson</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Follath</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Hellemans</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Herlitz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Luscher</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Pasic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Thelle</surname>
<given-names>D</given-names>
</string-name>. <article-title>The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina</article-title>. <source>Eur Heart J</source>. <year>2002</year>;<volume>23</volume>:<fpage>355</fpage>&#x02013;<lpage>370</lpage>.<pub-id pub-id-type="pmid">11846493</pub-id></mixed-citation></ref><ref id="jah31429-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah31429-cit-0006">
<string-name>
<surname>Henry</surname>
<given-names>TD</given-names>
</string-name>, <string-name>
<surname>Satran</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Jolicoeur</surname>
<given-names>EM</given-names>
</string-name>. <article-title>Treatment of refractory angina in patients not suitable for revascularization</article-title>. <source>Nat Rev Cardiol</source>. <year>2014</year>;<volume>11</volume>:<fpage>78</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">24366073</pub-id></mixed-citation></ref><ref id="jah31429-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah31429-cit-0007">
<string-name>
<surname>Dubois</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Claus</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Marsboom</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Pokreisz</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Vandenwijngaert</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Depelteau</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Streb</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Chaothawee</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Maes</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Gheysens</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Debyser</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Gillijns</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Pellens</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vandendriessche</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Chuah</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Collen</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Verbeken</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Belmans</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Van de Werf</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Bogaert</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Janssens</surname>
<given-names>S</given-names>
</string-name>. <article-title>Differential effects of progenitor cell populations on left ventricular remodeling and myocardial neovascularization after myocardial infarction</article-title>. <source>J Am Coll Cardiol</source>. <year>2010</year>;<volume>55</volume>:<fpage>2232</fpage>&#x02013;<lpage>2243</lpage>.<pub-id pub-id-type="pmid">20466204</pub-id></mixed-citation></ref><ref id="jah31429-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah31429-cit-0008">
<string-name>
<surname>Hendrickx</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Verdonck</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Van den Berge</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dickens</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Eriksson</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Vranckx</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Luttun</surname>
<given-names>A</given-names>
</string-name>. <article-title>Integration of blood outgrowth endothelial cells in dermal fibroblast sheets promotes full thickness wound healing</article-title>. <source>Stem Cells</source>. <year>2010</year>;<volume>28</volume>:<fpage>1165</fpage>&#x02013;<lpage>1177</lpage>.<pub-id pub-id-type="pmid">20506500</pub-id></mixed-citation></ref><ref id="jah31429-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah31429-cit-0009">
<string-name>
<surname>Vasa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fichtlscherer</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Aicher</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Adler</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Urbich</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zeiher</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Dimmeler</surname>
<given-names>S</given-names>
</string-name>. <article-title>Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease</article-title>. <source>Circ Res</source>. <year>2001</year>;<volume>89</volume>:<fpage>E1</fpage>&#x02013;<lpage>E7</lpage>.<pub-id pub-id-type="pmid">11440984</pub-id></mixed-citation></ref><ref id="jah31429-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah31429-cit-0010">
<string-name>
<surname>Thum</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hoeber</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Froese</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Klink</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Stichtenoth</surname>
<given-names>DO</given-names>
</string-name>, <string-name>
<surname>Galuppo</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Jakob</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tsikas</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Anker</surname>
<given-names>SD</given-names>
</string-name>, <string-name>
<surname>Poole&#x02010;Wilson</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Borlak</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ertl</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Bauersachs</surname>
<given-names>J</given-names>
</string-name>. <article-title>Age&#x02010;dependent impairment of endothelial progenitor cells is corrected by growth&#x02010;hormone&#x02010;mediated increase of insulin&#x02010;like growth&#x02010;factor&#x02010;1</article-title>. <source>Circ Res</source>. <year>2007</year>;<volume>100</volume>:<fpage>434</fpage>&#x02013;<lpage>443</lpage>.<pub-id pub-id-type="pmid">17234973</pub-id></mixed-citation></ref><ref id="jah31429-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah31429-cit-0011">
<string-name>
<surname>Kissel</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Lehmann</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Assmus</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Aicher</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Honold</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Fischer&#x02010;Rasokat</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Heeschen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Spyridopoulos</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Dimmeler</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zeiher</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>;<volume>49</volume>:<fpage>2341</fpage>&#x02013;<lpage>2349</lpage>.<pub-id pub-id-type="pmid">17572250</pub-id></mixed-citation></ref><ref id="jah31429-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah31429-cit-0012">
<string-name>
<surname>Walter</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Haendeler</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Reinhold</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rochwalsky</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Seeger</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Honold</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hoffmann</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Urbich</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lehmann</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Arenzana&#x02010;Seisdesdos</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Aicher</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Heeschen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Fichtlscherer</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zeiher</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Dimmeler</surname>
<given-names>S</given-names>
</string-name>. <article-title>Impaired CXCR4 signaling contributes to the reduced neovascularization capacity of endothelial progenitor cells from patients with coronary artery disease</article-title>. <source>Circ Res</source>. <year>2005</year>;<volume>97</volume>:<fpage>1142</fpage>&#x02013;<lpage>1151</lpage>.<pub-id pub-id-type="pmid">16254213</pub-id></mixed-citation></ref><ref id="jah31429-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah31429-cit-0013">
<string-name>
<surname>Fadini</surname>
<given-names>GP</given-names>
</string-name>, <string-name>
<surname>Sartore</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Albiero</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Baesso</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Murphy</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Menegolo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Grego</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Vigili de Kreutzenberg</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tiengo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Agostini</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Avogaro</surname>
<given-names>A</given-names>
</string-name>. <article-title>Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2006</year>;<volume>26</volume>:<fpage>2140</fpage>&#x02013;<lpage>2146</lpage>.<pub-id pub-id-type="pmid">16857948</pub-id></mixed-citation></ref><ref id="jah31429-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah31429-cit-0014">
<string-name>
<surname>Hill</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Zalos</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Halcox</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Schenke</surname>
<given-names>WH</given-names>
</string-name>, <string-name>
<surname>Waclawiw</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Quyyumi</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Finkel</surname>
<given-names>T</given-names>
</string-name>. <article-title>Circulating endothelial progenitor cells, vascular function, and cardiovascular risk</article-title>. <source>N Engl J Med</source>. <year>2003</year>;<volume>348</volume>:<fpage>593</fpage>&#x02013;<lpage>600</lpage>.<pub-id pub-id-type="pmid">12584367</pub-id></mixed-citation></ref><ref id="jah31429-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah31429-cit-0015">
<string-name>
<surname>Heeschen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lehmann</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Honold</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Assmus</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Aicher</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Walter</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zeiher</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Dimmeler</surname>
<given-names>S</given-names>
</string-name>. <article-title>Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>109</volume>:<fpage>1615</fpage>&#x02013;<lpage>1622</lpage>.<pub-id pub-id-type="pmid">15037527</pub-id></mixed-citation></ref><ref id="jah31429-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah31429-cit-0016">
<string-name>
<surname>Korff</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Augustin</surname>
<given-names>HG</given-names>
</string-name>. <article-title>Tensional forces in fibrillar extracellular matrices control directional capillary sprouting</article-title>. <source>J Cell Sci</source>. <year>1999</year>;<volume>112</volume>(<issue>Pt 19</issue>):<fpage>3249</fpage>&#x02013;<lpage>3258</lpage>.<pub-id pub-id-type="pmid">10504330</pub-id></mixed-citation></ref><ref id="jah31429-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jah31429-cit-0017">
<string-name>
<surname>Scholz</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Schaper</surname>
<given-names>W</given-names>
</string-name>. <article-title>Preconditioning of arteriogenesis</article-title>. <source>Cardiovasc Res</source>. <year>2005</year>;<volume>65</volume>:<fpage>513</fpage>&#x02013;<lpage>523</lpage>.<pub-id pub-id-type="pmid">15639491</pub-id></mixed-citation></ref><ref id="jah31429-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah31429-cit-0018">
<string-name>
<surname>Scholz</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Schaper</surname>
<given-names>W</given-names>
</string-name>. <article-title>Enhanced arteriogenesis in mice overexpressing erythropoietin</article-title>. <source>Cell Tissue Res</source>. <year>2006</year>;<volume>324</volume>:<fpage>395</fpage>&#x02013;<lpage>401</lpage>.<pub-id pub-id-type="pmid">16485134</pub-id></mixed-citation></ref><ref id="jah31429-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jah31429-cit-0019">
<string-name>
<surname>Werner</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kosiol</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Schiegl</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ahlers</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Walenta</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Link</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bohm</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nickenig</surname>
<given-names>G</given-names>
</string-name>. <article-title>Circulating endothelial progenitor cells and cardiovascular outcomes</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>353</volume>:<fpage>999</fpage>&#x02013;<lpage>1007</lpage>.<pub-id pub-id-type="pmid">16148285</pub-id></mixed-citation></ref><ref id="jah31429-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jah31429-cit-0020">
<string-name>
<surname>Massa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Campanelli</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Bonetti</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ferrario</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Marinoni</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Rosti</surname>
<given-names>V</given-names>
</string-name>. <article-title>Rapid and large increase of the frequency of circulating endothelial colony&#x02010;forming cells (ECFCs) generating late outgrowth endothelial cells in patients with acute myocardial infarction</article-title>. <source>Exp Hematol</source>. <year>2009</year>;<volume>37</volume>:<fpage>8</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">19013004</pub-id></mixed-citation></ref><ref id="jah31429-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jah31429-cit-0021">
<string-name>
<surname>Chu</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Jung</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>HK</given-names>
</string-name>, <string-name>
<surname>Sinn</surname>
<given-names>DI</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>EC</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Roh</surname>
<given-names>JK</given-names>
</string-name>. <article-title>Circulating endothelial progenitor cells as a new marker of endothelial dysfunction or repair in acute stroke</article-title>. <source>Stroke</source>. <year>2008</year>;<volume>39</volume>:<fpage>1441</fpage>&#x02013;<lpage>1447</lpage>.<pub-id pub-id-type="pmid">18356550</pub-id></mixed-citation></ref><ref id="jah31429-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jah31429-cit-0022">
<string-name>
<surname>Navarro&#x02010;Sobrino</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rosell</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hernandez&#x02010;Guillamon</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Penalba</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ribo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Alvarez&#x02010;Sabin</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Montaner</surname>
<given-names>J</given-names>
</string-name>. <article-title>Mobilization, endothelial differentiation and functional capacity of endothelial progenitor cells after ischemic stroke</article-title>. <source>Microvasc Res</source>. <year>2010</year>;<volume>80</volume>:<fpage>317</fpage>&#x02013;<lpage>323</lpage>.<pub-id pub-id-type="pmid">20594997</pub-id></mixed-citation></ref><ref id="jah31429-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jah31429-cit-0023">
<string-name>
<surname>Jodon de Villeroche</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Avouac</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ponceau</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ruiz</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Kahan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Boileau</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Uzan</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Allanore</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Enhanced late&#x02010;outgrowth circulating endothelial progenitor cell levels in rheumatoid arthritis and correlation with disease activity</article-title>. <source>Arthritis Res Ther</source>. <year>2010</year>;<volume>12</volume>:<fpage>R27</fpage>.<pub-id pub-id-type="pmid">20158894</pub-id></mixed-citation></ref><ref id="jah31429-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jah31429-cit-0024">
<string-name>
<surname>Thill</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Strunnikova</surname>
<given-names>NV</given-names>
</string-name>, <string-name>
<surname>Berna</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Gordiyenko</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Schmid</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Cousins</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Csaky</surname>
<given-names>KG</given-names>
</string-name>. <article-title>Late outgrowth endothelial progenitor cells in patients with age&#x02010;related macular degeneration</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2008</year>;<volume>49</volume>:<fpage>2696</fpage>&#x02013;<lpage>2708</lpage>.<pub-id pub-id-type="pmid">18515596</pub-id></mixed-citation></ref><ref id="jah31429-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jah31429-cit-0025">
<string-name>
<surname>Rignault&#x02010;Clerc</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bielmann</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Delodder</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Raffoul</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Waeber</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Liaudet</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Berger</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Feihl</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Rosenblatt&#x02010;Velin</surname>
<given-names>N</given-names>
</string-name>. <article-title>Functional late outgrowth endothelial progenitors isolated from peripheral blood of burned patients</article-title>. <source>Burns</source>. <year>2013</year>;<volume>39</volume>:<fpage>694</fpage>&#x02013;<lpage>704</lpage>.<pub-id pub-id-type="pmid">23102579</pub-id></mixed-citation></ref><ref id="jah31429-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jah31429-cit-0026">
<string-name>
<surname>Martin&#x02010;Ramirez</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kok</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Hofman</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bierings</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Creemers</surname>
<given-names>EE</given-names>
</string-name>, <string-name>
<surname>Meijers</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Voorberg</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pinto&#x02010;Sietsma</surname>
<given-names>SJ</given-names>
</string-name>. <article-title>Individual with subclinical atherosclerosis have impaired proliferation of blood outgrowth endothelial cells, which can be restored by statin therapy</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>:<fpage>e99890</fpage>.<pub-id pub-id-type="pmid">24955753</pub-id></mixed-citation></ref><ref id="jah31429-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jah31429-cit-0027">
<string-name>
<surname>Ingram</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Mead</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Meade</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Fenoglio</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mortell</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Pollok</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ferkowicz</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Gilley</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Yoder</surname>
<given-names>MC</given-names>
</string-name>. <article-title>Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood</article-title>. <source>Blood</source>. <year>2004</year>;<volume>104</volume>:<fpage>2752</fpage>&#x02013;<lpage>2760</lpage>.<pub-id pub-id-type="pmid">15226175</pub-id></mixed-citation></ref><ref id="jah31429-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jah31429-cit-0028">
<string-name>
<surname>Williamson</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Hamilton</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Reynolds</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Sipos</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Crocker</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Stringer</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Alexander</surname>
<given-names>YM</given-names>
</string-name>. <article-title>Age&#x02010;related impairment of endothelial progenitor cell migration correlates with structural alterations of heparan sulfate proteoglycans</article-title>. <source>Aging Cell</source>. <year>2013</year>;<volume>12</volume>:<fpage>139</fpage>&#x02013;<lpage>147</lpage>.<pub-id pub-id-type="pmid">23190312</pub-id></mixed-citation></ref><ref id="jah31429-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jah31429-cit-0029">
<string-name>
<surname>Ho</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Lai</surname>
<given-names>WH</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Au</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>Yip</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>NL</given-names>
</string-name>, <string-name>
<surname>Ng</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Lam</surname>
<given-names>FF</given-names>
</string-name>, <string-name>
<surname>Siu</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Tse</surname>
<given-names>HF</given-names>
</string-name>. <article-title>Reversal of endothelial progenitor cell dysfunction in patients with&#x000a0;type 2 diabetes using a conditioned medium of human embryonic stem cell&#x02010;derived endothelial cells</article-title>. <source>Diabetes Metab Res Rev</source>. <year>2012</year>;<volume>28</volume>:<fpage>462</fpage>&#x02013;<lpage>473</lpage>.<pub-id pub-id-type="pmid">22492468</pub-id></mixed-citation></ref><ref id="jah31429-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jah31429-cit-0030">
<string-name>
<surname>Tobler</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Freudenthaler</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Baumgartner&#x02010;Parzer</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Wolzt</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ludvik</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Nansalmaa</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Nowotny</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Seidinger</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Steiner</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Luger</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Artwohl</surname>
<given-names>M</given-names>
</string-name>. <article-title>Reduction of both number and proliferative activity of human endothelial progenitor cells in obesity</article-title>. <source>Int J Obes</source>. <year>2010</year>;<volume>34</volume>:<fpage>687</fpage>&#x02013;<lpage>700</lpage>.</mixed-citation></ref><ref id="jah31429-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jah31429-cit-0031">
<string-name>
<surname>Toshner</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Voswinckel</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Southwood</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Al&#x02010;Lamki</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Howard</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Marchesan</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Suntharalingam</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Soon</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Exley</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Stewart</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hecker</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Gehling</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Seeger</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Pepke&#x02010;Zaba</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Morrell</surname>
<given-names>NW</given-names>
</string-name>. <article-title>Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2009</year>;<volume>180</volume>:<fpage>780</fpage>&#x02013;<lpage>787</lpage>.<pub-id pub-id-type="pmid">19628780</pub-id></mixed-citation></ref><ref id="jah31429-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jah31429-cit-0032">
<string-name>
<surname>Paschalaki</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Starke</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Mercado</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Margariti</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gorgoulis</surname>
<given-names>VG</given-names>
</string-name>, <string-name>
<surname>Randi</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Barnes</surname>
<given-names>PJ</given-names>
</string-name>. <article-title>Dysfunction of endothelial progenitor cells from smokers and chronic obstructive pulmonary disease patients due to increased DNA damage and senescence</article-title>. <source>Stem Cells</source>. <year>2013</year>;<volume>31</volume>:<fpage>2813</fpage>&#x02013;<lpage>2826</lpage>.<pub-id pub-id-type="pmid">23897750</pub-id></mixed-citation></ref><ref id="jah31429-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jah31429-cit-0033">
<string-name>
<surname>Fernandez</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Obi&#x02010;onuoha</surname>
<given-names>IC</given-names>
</string-name>, <string-name>
<surname>Wallace</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Satterwhite</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Truskey</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Reichert</surname>
<given-names>WM</given-names>
</string-name>. <article-title>Late&#x02010;outgrowth endothelial progenitors from patients with coronary artery disease: endothelialization of confluent stromal cell layers</article-title>. <source>Acta Biomater</source>. <year>2014</year>;<volume>10</volume>:<fpage>893</fpage>&#x02013;<lpage>900</lpage>.<pub-id pub-id-type="pmid">24140604</pub-id></mixed-citation></ref><ref id="jah31429-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jah31429-cit-0034">
<string-name>
<surname>Stroncek</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Grant</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Povsic</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Truskey</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Reichert</surname>
<given-names>WM</given-names>
</string-name>. <article-title>Comparison of endothelial cell phenotypic markers of late&#x02010;outgrowth endothelial progenitor cells isolated from patients with coronary artery disease and healthy volunteers</article-title>. <source>Tissue Eng Part A</source>. <year>2009</year>;<volume>15</volume>:<fpage>3473</fpage>&#x02013;<lpage>3486</lpage>.<pub-id pub-id-type="pmid">19435420</pub-id></mixed-citation></ref><ref id="jah31429-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jah31429-cit-0035">
<string-name>
<surname>Chen</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Herrmann</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Jordan</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Gloviczki</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Lerman</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Textor</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Lerman</surname>
<given-names>LO</given-names>
</string-name>. <article-title>Preserved function of late&#x02010;outgrowth endothelial cells in medically treated hypertensive patients under well&#x02010;controlled conditions</article-title>. <source>Hypertension</source>. <year>2014</year>;<volume>64</volume>:<fpage>808</fpage>&#x02013;<lpage>814</lpage>.<pub-id pub-id-type="pmid">25047576</pub-id></mixed-citation></ref><ref id="jah31429-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jah31429-cit-0036">
<string-name>
<surname>Jakobsson</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nilsson</surname>
<given-names>GE</given-names>
</string-name>. <article-title>Prediction of sampling depth and photon pathlength in laser Doppler flowmetry</article-title>. <source>Med Biol Eng Comput</source>. <year>1993</year>;<volume>31</volume>:<fpage>301</fpage>&#x02013;<lpage>307</lpage>.<pub-id pub-id-type="pmid">8412384</pub-id></mixed-citation></ref><ref id="jah31429-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jah31429-cit-0037">
<string-name>
<surname>Schaper</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Scholz</surname>
<given-names>D</given-names>
</string-name>. <article-title>Factors regulating arteriogenesis</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2003</year>;<volume>23</volume>:<fpage>1143</fpage>&#x02013;<lpage>1151</lpage>.<pub-id pub-id-type="pmid">12676799</pub-id></mixed-citation></ref><ref id="jah31429-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jah31429-cit-0038">
<string-name>
<surname>Pipp</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Heil</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Issbrucker</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ziegelhoeffer</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>van den Heuvel</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Weich</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Fernandez</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Golomb</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Carmeliet</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Schaper</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Clauss</surname>
<given-names>M</given-names>
</string-name>. <article-title>VEGFR&#x02010;1&#x02010;selective VEGF homologue PLGF is arteriogenic: evidence for a monocyte&#x02010;mediated mechanism</article-title>. <source>Circ Res</source>. <year>2003</year>;<volume>92</volume>:<fpage>378</fpage>&#x02013;<lpage>385</lpage>.<pub-id pub-id-type="pmid">12600898</pub-id></mixed-citation></ref><ref id="jah31429-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jah31429-cit-0039">
<string-name>
<surname>Heil</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schaper</surname>
<given-names>W</given-names>
</string-name>. <article-title>Pathophysiology of collateral development</article-title>. <source>Coron Artery Dis</source>. <year>2004</year>;<volume>15</volume>:<fpage>373</fpage>&#x02013;<lpage>378</lpage>.<pub-id pub-id-type="pmid">15492584</pub-id></mixed-citation></ref><ref id="jah31429-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jah31429-cit-0040">
<string-name>
<surname>Tressel</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ni</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Velasquez&#x02010;Castano</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>WR</given-names>
</string-name>, <string-name>
<surname>Yoon</surname>
<given-names>YS</given-names>
</string-name>, <string-name>
<surname>Jo</surname>
<given-names>H</given-names>
</string-name>. <article-title>Angiopoietin&#x02010;2 stimulates blood flow recovery after femoral artery occlusion by inducing inflammation and arteriogenesis</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2008</year>;<volume>28</volume>:<fpage>1989</fpage>&#x02013;<lpage>1995</lpage>.<pub-id pub-id-type="pmid">18772493</pub-id></mixed-citation></ref><ref id="jah31429-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="jah31429-cit-0041">
<string-name>
<surname>Qin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Trenkwalder</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chillo</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Deindl</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kupatt</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hinkel</surname>
<given-names>R</given-names>
</string-name>. <article-title>Early vessel destabilization mediated by angiopoietin&#x02010;2 and subsequent vessel maturation via angiopoietin&#x02010;1 induce functional neovasculature after ischemia</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>:<fpage>e61831</fpage>.<pub-id pub-id-type="pmid">23613948</pub-id></mixed-citation></ref><ref id="jah31429-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="jah31429-cit-0042">
<string-name>
<surname>Lekas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lekas</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Mei</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Deng</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Dumont</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Stewart</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Tie2&#x02010;dependent neovascularization of the ischemic hindlimb is mediated by angiopoietin&#x02010;2</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>:<fpage>e43568</fpage>.<pub-id pub-id-type="pmid">23049737</pub-id></mixed-citation></ref><ref id="jah31429-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="jah31429-cit-0043">
<string-name>
<surname>Dewerchin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Carmeliet</surname>
<given-names>P</given-names>
</string-name>. <article-title>PLGF: a multitasking cytokine with disease&#x02010;restricted activity</article-title>. <source>Cold Spring Harb Perspect Med</source>. <year>2012</year>;<volume>2</volume>:<fpage>a011056</fpage>.<pub-id pub-id-type="pmid">22908198</pub-id></mixed-citation></ref><ref id="jah31429-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="jah31429-cit-0044">
<string-name>
<surname>Luttun</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tjwa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Moons</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Angelillo&#x02010;Scherrer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Liao</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Nagy</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Hooper</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Priller</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>De Klerck</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Compernolle</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Daci</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Bohlen</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Dewerchin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Herbert</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Fava</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Matthys</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Carmeliet</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Collen</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Dvorak</surname>
<given-names>HF</given-names>
</string-name>, <string-name>
<surname>Hicklin</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Carmeliet</surname>
<given-names>P</given-names>
</string-name>. <article-title>Revascularization of ischemic tissues by PLGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti&#x02010;Flt1</article-title>. <source>Nat Med</source>. <year>2002</year>;<volume>8</volume>:<fpage>831</fpage>&#x02013;<lpage>840</lpage>.<pub-id pub-id-type="pmid">12091877</pub-id></mixed-citation></ref><ref id="jah31429-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="jah31429-cit-0045">
<string-name>
<surname>Babiak</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schumm</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Wangler</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Loukas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Dombrowski</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Matuschek</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kotzerke</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Dehio</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Waltenberger</surname>
<given-names>J</given-names>
</string-name>. <article-title>Coordinated activation of VEGFR&#x02010;1 and VEGFR&#x02010;2 is a potent arteriogenic stimulus leading to enhancement of regional perfusion</article-title>. <source>Cardiovasc Res</source>. <year>2004</year>;<volume>61</volume>:<fpage>789</fpage>&#x02013;<lpage>795</lpage>.<pub-id pub-id-type="pmid">14985076</pub-id></mixed-citation></ref><ref id="jah31429-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="jah31429-cit-0046">
<string-name>
<surname>Roncal</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Buysschaert</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Chorianopoulos</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Georgiadou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Meilhac</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Demol</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Michel</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Vinckier</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Moons</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Carmeliet</surname>
<given-names>P</given-names>
</string-name>. <article-title>Beneficial effects of prolonged systemic administration of PLGF on late outcome of post&#x02010;ischaemic myocardial performance</article-title>. <source>J Pathol</source>. <year>2008</year>;<volume>216</volume>:<fpage>236</fpage>&#x02013;<lpage>244</lpage>.<pub-id pub-id-type="pmid">18729077</pub-id></mixed-citation></ref><ref id="jah31429-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="jah31429-cit-0047">
<string-name>
<surname>Liu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Claus</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Reyns</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Verhamme</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pokreisz</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Vandenwijngaert</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dubois</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Vanhaecke</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Verbeken</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Bogaert</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Janssens</surname>
<given-names>S</given-names>
</string-name>. <article-title>Placental growth factor increases regional myocardial blood flow and contractile function in chronic myocardial ischemia</article-title>. <source>Am J Physiol Heart Circ Physiol</source>. <year>2013</year>;<volume>304</volume>:<fpage>H885</fpage>&#x02013;<lpage>H894</lpage>.<pub-id pub-id-type="pmid">23316060</pub-id></mixed-citation></ref></ref-list></back></article>